SSGC 10-K 2019 - Equibles

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM10-K

[X]ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Forthe fiscal year ended July 31, 2019

[ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Forthe transition period from ________ to ________

Commissionfile number: 001-36564

HealthcareIntegrated Technologies, Inc.

(Exact Name of Registrant as Specified in its Charter)

Nevada	46-3052781
(State<br> or Other Jurisdiction of<br><br> Incorporation or Organization)	(I.R.S.<br> Employer<br><br> Identification No.)

1462Rudder Lane

Knoxville,TN 37919

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (865) 719-8160

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to section 12(g) of the Act:

CommonStock, $0.001 par value

(Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined by Rule 405 of the Securities Act. Yes [ ] No [X]

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes [ ] No [X]

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [ ] No [X]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (ss.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [ ] No [X]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large<br> accelerated filer	[ ]	Accelerated<br> filer	[ ]
Non-accelerated<br> filer	[ ]	Smaller<br> reporting company	[X]
(Do<br> not check if a smaller reporting company)		Emerging<br> growth company	[ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

The aggregate market value of the outstanding common stock, other than shares held by persons who may be deemed affiliates of the registrant, computed by reference to the closing sales price for the registrant’s common stock on January 31, 2019 (the last business day of the registrant’s most recently completed second quarter), as reported on the OTC Pink market, was approximately $3,915,794. As of March 18, 2020, there were 33,487,500 shares of common stock of the registrant outstanding.

Documents Incorporated by Reference: None.

TABLEOF CONTENTS

PART<br> I	4
ITEM<br> 1. BUSINESS.	4
ITEM<br> 1A. RISK FACTORS.	5
ITEM<br> 1B. UNRESOLVED STAFF COMMENTS.	12
ITEM<br> 2. PROPERTIES.	12
ITEM<br> 3. LEGAL PROCEEDINGS.	12
ITEM<br> 4. MINE SAFETY DISCLOSURES.	12
PART<br> II	13
ITEM<br> 5. MARKET FOR OUR COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.	13
ITEM<br> 6. SELECTED FINANCIAL DATA.	14
ITEM<br> 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.	14
ITEM<br> 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.	20
ITEM<br> 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.	20
ITEM<br> 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.	21
ITEM<br> 9A. CONTROLS AND PROCEDURES.	22
ITEM<br> 9B. OTHER INFORMATION	23
PART<br> III	24
ITEM<br> 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.	24
ITEM<br> 11. EXECUTIVE COMPENSATION.	28
ITEM<br> 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.	29
ITEM<br> 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.	30
ITEM<br> 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.	31
PART<br> IV	32
ITEM<br> 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES	32
SIGNATURES	33

| 2 |

| --- |

EXPLANATORYNOTE

Healthcare Integrated Technologies, Inc. (formerly known as Grasshopper Staffing, Inc.) is filing this comprehensive annual report on Form 10-K for the fiscal years ending July 31, 2019 and July 31, 2018, and the quarterly periods ended April 30, 2018, October 31, 2018, January 31, 2019, April 30, 2019, October 31, 2019, and January 31, 2020 (the “Comprehensive Form 10-K”) as part of its effort to become current in its filing obligations under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This Comprehensive Form 10-K is our first periodic filing with the Securities and Exchange Commission (the “SEC”) since the filing of our quarterly report on Form 10-Q for the quarterly period ended January 31, 2018. Included in this Comprehensive 10-K are our audited financial statements for the fiscal years ended July 31, 2019 and July 31, 2018, which have not been previously filed with the SEC. In addition, the Comprehensive 10-K also includes unaudited quarterly financial statements for the quarterly periods ended April 30, 2018, October 31, 2018, January 31, 2019, April 30, 2019, October 31, 2019, and January 31, 2020.

CAUTIONARYNOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K (this “Report”) contains “forward-looking statements” within the meaning of the Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as “anticipate,” “believe,” “estimate,” “intend,” “could,” “should,” “would,” “may,” “seek,” “plan,” “might,” “will,” “expect,” “predict,” “project,” “forecast,” “potential,” “continue”, negatives thereof or similar expressions. These forward-looking statements are found at various places throughout this Annual Report and include information concerning: possible or assumed future results of our operations; business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future operations, future cash needs, business plans and future financial results; and any other statements that are not historical facts.

From time to time, forward-looking statements also are included in our other periodic reports on Forms 10-Q and 8-K, in our press releases, in our presentations, on our website and in other materials released to the public. Any or all the forward-looking statements included in this Annual Report and in any other reports or public statements made by us are not guarantees of future performance and may turn out to be inaccurate. These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. Considering these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report. All subsequent written and oral forward-looking statements concerning other matters addressed in this Annual Report and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Annual Report.

Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.

For discussion of factors that we believe could cause our actual results to differ materially from expected and historical results see “Item 1A - Risk Factors” below.

| 3 |

| --- |

PARTI

ITEM1. BUSINESS.

Overview

As used in this Annual Report, “we,” “us,” “our,” “Healthcare Integrated Technologies,” “Company,” or “our Company” refers to Healthcare Integrated Technologies, Inc. and our subsidiary IndeLiving Holdings, Inc. (“Inde” or “IndeLiving”).

Healthcare Integrated Technologies, Inc. (the “Company”), is a healthcare technology company whose primary operations are through our IndeLiving subsidiary, which we acquired in March 2018. With the acquisition of IndeLiving, our core focus changed, and our operations through our Grasshopper Staffing, Inc. (“Grasshopper Colorado”) subsidiary ceased in February 2019. We also changed our name to Healthcare Integrated Technologies, Inc., to better reflect our new operations. As a result, our operations, management and board of directors, and our business in general have undergone a substantial change and the Company has experienced a change in control since the closing of the IndeLiving acquisition.

Founded in 2016 and based in Knoxville, Tennessee, IndeLiving has developed a health monitoring system for assisted living centers and private homes. IndeLiving is a development stage company that uses proprietary technology to monitor seniors in real time by both caregivers and family without the need for the senior to wear any type of monitoring device. The monitoring system is customized to the needs of the individual senior and, if applicable, to assisted living facility requirements. It provides real-time information to monitoring stations at the assisted living facilities. It also can be set up to provide real time information via text, voice, email, and a mobile phone application to family members or other caregivers. The residential model called “Inde Companion” is a monitoring concept with custom modifications that can be applied to individual seniors in a variety of applications including seniors living independently in their own home, with family members, or in an assisted living or retirement community.

We have secured a contract with a hardware supplier, Vayyar Imaging, Ltd., to produce the monitoring devices as of August 7, 2019, which requires us to purchase $2,000,000 in product by July 31, 2020. We are currently further developing the related software for both a mobile phone application and a desktop “dashboard” to be used by assisted living facilities. We are engaged in marketing and sales of our product to assisted living facilities.

OurHistory

The Company has had three distinct phases and businesses. First, we were incorporated in the state of Nevada on June 25, 2013 as Tomichi Creek Outfitters, aiming to provide professionally guided big game hunts in Sargents, Colorado which is approximately four hours southwest from Denver. This area of the country is home to trophy size Elk and Mule Deer. Our secondary business included offering guided scenic tours on the western slopes of the Rocky Mountains. Every season offers a diversified plethora of wildlife and stunning scenic views. Our Chief Executive Officer (“CEO”) and sole director at that time was Jeremy Gindro.

| 4 |

| --- |

Second, on March 2, 2015, the Company entered into a Business Acquisition Agreement and share exchange under which we acquired the business and assets of Grasshopper Colorado, formed in the state of Colorado on January 13, 2015. The exchange for $10,651 was represented by 250,000 shares of the Company’s common stock in exchange for all the outstanding shares of Grasshopper Colorado. The assets purchased include the trademark and website, office supplies and office furniture. On November 2, 2015 we filed a Certificate of Amendment to our Articles of Incorporation changing the name of our Company from Tomichi Creek Outfitters to Grasshopper Staffing, Inc. Grasshopper Colorado was operating as a wholly-owned subsidiary of the Company and was the primary operation of our business until the acquisition of IndeLiving Holdings Inc., on March 13, 2018. Our management consisted of Melanie Osterman as CEO, and Jeremy Gindro who was our sole director.

Third, we acquired IndeLiving and changed our name to Healthcare Integrated Technologies, Inc. Our current operations are described above. With the acquisition of IndeLiving, we had another change in management, and Scott M. Boruff became CEO and sole director of the Company.

Employees

At July 31, 2018, we had 24 employees.

At July 31, 2019, we had 1 employee.

AvailableInformation

We electronically file certain documents with the Securities and Exchange Commission (the SEC). We file annual reports on Form 10-K; quarterly reports on Form 10-Q; and current reports on Form 8-K (as appropriate); along with any related amendments and supplements thereto. From time-to-time, we may also file registration statements and related documents in connection with equity or debt offerings. You may read and copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington, DC 20549. You may obtain information regarding the Public Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an internet website at www.sec.gov that contains reports and other information regarding registrants that file electronically with the SEC.

ITEM1A. RISK FACTORS.

RisksRelated to Economic and Market Conditions

GeneralEconomic and Financial Conditions

The success of any investment activity is influenced by general economic and financial conditions, all of which are beyond the control of the Company. These conditions, such as the recent global economic crisis and significant downturns in the financial markets, may materially adversely affect our operating results, financial condition and ability to implement our business strategy and/or meet our return objectives.

The recent global outbreak of COVID-19 (more commonly known as the Coronavirus) has disrupted economic markets and the prolonged economic impact is uncertain. Some economists and major investment banks have expressed concern that the continued spread of the virus globally could lead to a world-wide economic downturn. Many manufacturers of goods in China and other countries have seen a downturn in production due to the suspension of business and temporary closure of factories in an attempt to curb the spread of the illness. As the impact of the Coronavirus spreads to other parts of the world, similar impacts may occur with respect to affected countries.

RisksRelated to Our Business

TheCompany’s industry is highly competitive and we have less capital and resources than many of our competitors which may givethem an advantage in developing and marketing products similar to ours or make our products obsolete.

We are involved in a highly competitive industry where we may compete with numerous other companies who offer alternative methods or approaches, who may have far greater resources, more experience, and personnel perhaps more qualified than we do. Such resources may give our competitors an advantage in developing and marketing products similar to ours or products that make our products obsolete. There can be no assurance that we will be able to successfully compete against these other entities.

| 5 |

| --- |

TheCompany may be unable to respond to the rapid technological change in its industry and such change may increase costs and competitionthat may adversely affect its business

Rapidly changing technologies, frequent new product and service introductions and evolving industry standards characterize the Company’s market. The continued growth of the Internet and intense competition in the Company’s industry exacerbate these market characteristics. The Company’s future success will depend on its ability to adapt to rapidly changing technologies by continually improving the performance features and reliability of its products and services. The Company may experience difficulties that could delay or prevent the successful development, introduction or marketing of its products and services. In addition, any new enhancements must meet the requirements of its current and prospective users and must achieve significant market acceptance. The Company could also incur substantial costs if it needs to modify its products and services or infrastructures to adapt to these changes.

The Company also expects that new competitors may introduce products, systems or services that are directly or indirectly competitive with the Company. These competitors may succeed in developing, products, systems and services that have greater functionality or are less costly than the Company’s products, systems and services, and may be more successful in marketing such products, systems and services. Technological changes have lowered the cost of operating communications and computer systems and purchasing software. These changes reduce the Company’s cost of providing services but also facilitate increased competition by reducing competitors’ costs in providing similar services. This competition could increase price competition and reduce anticipated profit margins.

| 6 |

| --- |

TheCompany’s services are new and its industry is evolving.

You should consider the Company’s prospects considering the risks, uncertainties and difficulties frequently encountered by companies in their early stage of development. To be successful in this industry, the Company must, among other things:

●	develop<br> and introduce functional and attractive services;
●	attract<br> and maintain a large base of customers;
●	increase<br> awareness of the Company brand and develop consumer loyalty;
●	respond<br> to competitive and technological developments;
●	build<br> an operations structure to support the Company business; and
●	attract,<br> retain and motivate qualified personnel.

The Company cannot guarantee that it will succeed in achieving these goals, and its failure to do so would have a material adverse effect on its business, prospects, financial condition and operating results.

The Company’s products and services are new and are in the early stages of development. The Company is not certain that these products and services will function as anticipated or be desirable to its intended market. Also, some of the Company’s products and services may have limited functionalities, which may limit their appeal to consumers and put the Company at a competitive disadvantage. If the Company’s current or future products and services fail to function properly or if the Company does not achieve or sustain market acceptance, it could lose customers or could be subject to claims which could have a material adverse effect on the Company business, financial condition and operating results.

RisksRelated to Our Company

Uncertaintyof profitability

Our business strategy may result in increased volatility of revenues and earnings. As we will only develop a limited number of products and services at a time, our overall success will depend on a limited number of products and services, which may cause variability and unsteady profits and losses depending on the products and services offered.

Our revenues and our profitability may be adversely affected by economic conditions and changes in the market. Our business is also subject to general economic risks that could adversely impact the results of operations and financial condition.

Because of the anticipated nature of the products and services that we will attempt to develop, it is difficult to accurately forecast revenues and operating results and these items could fluctuate in the future due to several factors. These factors may include, among other things, the following:

●	Our<br> ability to raise sufficient capital to take advantage of opportunities and generate sufficient revenues to cover expenses.
●	Our<br> ability to source strong opportunities with sufficient risk adjusted returns.
●	Our<br> ability to manage our capital and liquidity requirements based on changing market conditions generally.
●	The<br> acceptance of the terms and conditions of our licenses and/or the acceptance of our royalties and fees.
●	The<br> amount and timing of operating and other costs and expenses.
●	The<br> nature and extent of competition from other companies that may reduce market share and create pressure on pricing and investment<br> return expectations.
●	Adverse<br> changes in the national and regional economies in which we will participate, including, but not limited to, changes in our<br> performance, capital availability, and market demand.
●	Adverse<br> changes in the projects in which we plan to invest which result from factors beyond our control, including, but not limited<br> to, a change in circumstances, capacity and economic impacts.
●	Changes<br> in laws, regulations, accounting, taxation, and other requirements affecting our operations and business.
●	Our<br> operating results may fluctuate from year to year due to the factors listed above and others not listed. At times, these fluctuations<br> may be significant.

| 7 |

| --- |

Ourindependent auditors’ report for the fiscal years ended July 31, 2019 and 2018 have expressed doubts about our ability tocontinue as a going concern

Due to the uncertainty of our ability to meet our current operating and capital expenses, in our audited annual financial statements as of and for the years ended July 31, 2019 and 2018 our independent auditors included a note to our financial statements regarding concerns about our ability to continue as a going concern. We have incurred recurring losses and have generated limited revenue since inception. These factors and our need for additional financing to effectively execute our business plan, raise substantial doubt about our ability to continue as a going concern. The presence of the going concern note to our financial statements may have an adverse impact on the relationships we are developing and plan to develop with third parties as we continue the commercialization of our products and could make it challenging and difficult for us to raise additional financing, all of which could have a material adverse impact on our business and prospects and result in a significant or complete loss of your investment.

COVID-19could adversely impact our business

In December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 has spread to multiple countries, including the United States, and several European countries. If COVID-19 continues to spread in the United States, we expect to experience disruptions that could adversely impact our business. The spread of COVID-19 has disrupted the United States’ healthcare and healthcare regulatory systems which could divert healthcare resources away from our products. It is unknown how long these disruptions could continue, were they to occur. Additionally, COVID-19’s spread, which has had a broad global impact, including restrictions on travel and quarantine polices put into place by businesses and governments, may materially affect us economically by causing disruptions in our supply chain or distribution channels. As the global outbreak of COVID-19 continues to rapidly evolve, the extent to which COVID-19 may impact our business will depend on future developments, which are highly uncertain and cannot be predicted.

Managementof growth will be necessary for us to be competitive

Successful expansion of our business will depend on our ability to effectively attract and manage staff, strategic business relationships, and shareholders. Specifically, we will need to hire skilled management and technical personnel as well as manage partnerships to navigate shifts in the general economic environment. Expansion has the potential to place significant strains on financial, management, and operational resources, yet failure to expand will inhibit our profitability goals.

Weare entering a potentially highly competitive market

The markets for the healthcare and senior monitoring industries are competitive and evolving. We face strong competition from larger companies that may be in the process of offering similar products and services to ours. Many of our current and potential competitors have longer operating histories, significantly greater financial, marketing and other resources and larger client bases than we have (or may be expected to have).

Given the rapid changes affecting the global, national, and regional economies generally, and the healthcare industry specifically, we may not be able to create and maintain a competitive advantage in the marketplace. Our success will depend on our ability to keep pace with any market, legal and regulatory changes as well as competitive pressures. Any failure by us to anticipate or respond adequately to such changes could have a material adverse effect on our financial condition, operating results, liquidity and cash flow.

| 8 |

| --- |

Ifwe fail to establish and maintain an effective system of internal control, we may not be able to report our financial resultsaccurately or to prevent fraud. Any ability to report and file our financial results accurately and timely could harm our reputationand adversely impact the future trading price of our common stock.

Effective internal control is necessary for us to provide reliable financial reports and prevent fraud. If we cannot provide reliable financial reports or prevent fraud, we may not be able to manage our business as effectively as we would if an effective control environment existed, and our business and reputation with investors may be harmed. As a result, our small size and any current internal control deficiencies may adversely affect our financial condition, results of operation and access to capital.

We currently have insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of US GAAP and SEC disclosure requirements. Additionally, there is a lack of formal process and timeline for closing the books and records at the end of each reporting period and such weaknesses restrict the Company’s ability to timely gather, analyze and report information relative to the financial statements.

Because of the Company’s limited resources, there are limited controls over information processing. There is inadequate segregation of duties consistent with control objectives. Our Company’s management is composed of a small number of individuals resulting in a situation where limitations on segregation of duties exist. In order to remedy this situation, we would need to hire additional staff.

TheCompany’s failure to continue to attract, train, or retain highly qualified personnel could harm the company’s business.

The Company’s success also depends on the Company’s ability to attract, train, and retain qualified personnel, specifically those with management and product development skills. In particular, the Company must hire additional skilled personnel to further the Company’s research and development efforts. Competition for such personnel is intense. If the Company fails in attracting new personnel or retaining and motivating the Company’s current personnel, the Company’s business could be harmed.

RisksRelated to Our Common Stock

Becausewe will likely issue additional shares of our common stock, investment in our Company could be subject to substantial dilution.

Investors’ interests in our company will be diluted and investors may suffer dilution in their net book value per share when we issue additional shares. We are authorized to issue 200,000,000 shares of common stock, $0.001 par value per share. As of March 18, 2020, there were 33,487,500 shares of our common stock issued and outstanding. We anticipate that all or at least some of our future funding, if any, will be in the form of equity financing from the sale of our common stock. If we do sell more common stock, investors’ investment in our company will likely be diluted. Dilution is the difference between what you pay for your stock and the net tangible book value per share immediately after the additional shares are sold by us. If dilution occurs, any investment in our company’s common stock could seriously decline in value.

| 9 |

| --- |

Tradingin our common stock on the OTC Pink has been subject to wide fluctuations.

Our common stock is currently quoted for public trading on the OTC Pink. The trading price of our common stock has been subject to wide fluctuations. Trading prices of our common stock may fluctuate in response to several factors, many of which will be beyond our control. The stock market has generally experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of companies with no current business operation. There can be no assurance that trading prices and price earnings ratios previously experienced by our common stock will be matched or maintained. These broad market and industry factors may adversely affect the market price of our common stock, regardless of our operating performance. In the past, following periods of volatility in the market price of a company’s securities, securities class-action litigation has often been instituted. Such litigation, if instituted, could result in substantial costs for us and a diversion of management’s attention and resources.

OurCertificate of Incorporation and by-laws provides for indemnification of officers and directors at our expense and limit theirliability which may result in a major cost to us and hurt the interests of our shareholders because corporate resources may beexpended for the benefit of officers and/or directors.

Our Certificate of Incorporation and By-Laws include provisions that fully eliminate the personal liability of our directors for monetary damages to the fullest extent possible under the laws of the State of Nevada or other applicable law. These provisions eliminate the liability of our directors and our shareholders for monetary damages arising out of any violation of a director of his fiduciary duty of due care. Under Nevada law, however, such provisions do not eliminate the personal liability of a director for (i) breach of the director’s duty of loyalty, (ii) acts or omissions not in good faith or involving intentional misconduct or knowing violation of law, (iii) payment of dividends or repurchases of stock other than from lawfully available funds, or (iv) any transaction from which the director derived an improper benefit. These provisions do not affect a director’s liabilities under the federal securities laws or the recovery of damages by third parties.

Wedo not intend to pay dividends on any investment in the shares of stock of our Company and any gain on an investment in our Companywill need to come through an increase in our stock’s price, which may never happen.

We have never paid any cash dividends and currently do not intend to pay any dividends for the foreseeable future. To the extent that we require additional funding currently not provided for in our financing plan, our funding sources may prohibit the payment of a dividend. Because we do not intend to declare dividends, any gain on an investment in our company will need to come through an increase in the stock’s price. This may never occur and investors may lose all their investment in our company.

| 10 |

| --- |

Becauseour securities are subject to penny stock rules, you may have difficulty reselling your shares.

Our shares as penny stocks, are covered by Section 15(g) of the Securities Exchange Act of 1934 which imposes additional sales practice requirements on broker/dealers who sell our company’s securities including the delivery of a standardized disclosure document; disclosure and confirmation of quotation prices; disclosure of compensation the broker/dealer receives; and, furnishing monthly account statements. These rules apply to companies whose shares are not traded on a national stock exchange, trade at less than $5.00 per share, or who do not meet certain other financial requirements specified by the Securities and Exchange Commission.

These rules require brokers who sell “penny stocks” to persons other than established customers and “accredited investors” to complete certain documentation, make suitability inquiries of investors, and provide investors with certain information concerning the risks of trading in such penny stocks. These rules may discourage or restrict the ability of brokers to sell our shares of common stock and may affect the secondary market for our shares of common stock. These rules could also hamper our ability to raise funds in the primary market for our shares of common stock.

FINRAsales practice requirements may also limit a stockholder’s ability to buy and sell our stock.

In addition to the “penny stock” rules described above, the Financial Industry Regulatory Authority (known as “FINRA”) has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least some customers. FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common shares, which may limit your ability to buy and sell our stock and have an adverse effect on the market for our shares.

Therecould be unidentified risks involved with an investment in our securities

The foregoing risk factors are not a complete list or explanation of the risks involved with an investment in the securities. Additional risks will likely be experienced that are not presently foreseen by the Company. Prospective investors must not construe this information provided herein as constituting investment, legal, tax or other professional advice. Before making any decision to invest in our securities, you should read this entire prospectus and consult with your own investment, legal, tax and other professional advisors. An investment in our securities is suitable only for investors who can assume the financial risks of an investment in the Company for an indefinite period and who can afford to lose their entire investment. The Company makes no representations or warranties of any kind with respect to the likelihood of the success or the business of the Company, the value of our securities, any financial returns that may be generated or any tax benefits or consequences that may result from an investment in the Company.

| 11 |

| --- |

ITEM1B. UNRESOLVED STAFF COMMENTS.

Not applicable.

ITEM2. PROPERTIES.

None.

ITEM3. LEGAL PROCEEDINGS.

The Company is currently not involved in any litigation that the Company believes could have a materially adverse effect on the Company’s financial condition or results of operations. On January 2, 2020, a sworn account lawsuit was filed against our IndeLiving Holdings, Inc. (“IndeLiving”) subsidiary and our CEO Scott M. Boruff by our previous Certified Public Accounting Firm, RBSM LLP demanding payment of $28,007 for services rendered. We have filed our Answer and IndeLiving filed a breach of contract Counterclaim on February 24, 2020 demanding repayment of a $7,500 retainer paid to RBSM LLP by IndeLiving for services that we allege were not provided. Given the early state of the proceedings in this case, we currently cannot assess the probability of losses, but we can reasonably estimate that the range of losses in this case will be immaterial since the full amount of the lawsuit has previously been recorded in the consolidated financial statements.

ITEM4. MINE SAFETY DISCLOSURES.

Not applicable.

| 12 |

| --- |

PARTII

ITEM5. MARKET FOR OUR COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

(a)Market Information

Our common stock is quoted on the OTC Pink under the symbol “HITC”. The OTC Pink is a quotation service that displays real-time quotes, last-sale prices, and volume information in over-the-counter equity securities.

The following table shows, for the periods indicated, the high and low bid prices per share of the Company’s common Stock as reported by the OTC Pink quotation service. The quotations reflect inter-dealer prices, without retail mark-up, mark-down or commissions, and may not necessarily represent actual transactions.

	High		Low
Fiscal<br> Year 2018
First quarter<br> ended October 31, 2017	$	0.80	$	0.35
Second quarter<br> ended January 31, 2018	$	1.31	$	0.70
Third quarter<br> ended April 30, 2018	$	1.62	$	1.20
Fourth quarter<br> ended July 31, 2018	$	1.57	$	0.50
Fiscal<br> Year 2019
First quarter<br> ended October 31, 2018	$	0.65	$	0.30
Second quarter<br> ended January 31, 2019	$	0.45	$	0.30
Third quarter<br> ended April 30, 2019	$	0.47	$	0.12
Fourth quarter<br> ended July 31, 2019	$	0.20	$	0.12

(b)Holders

As of March 18, 2020, there were 48 stockholders of record. Because shares of the Company’s common stock are held by depositaries, brokers and other nominees, the number of beneficial holders of the Company’s shares is larger than the number of stockholders of record.

(c)Dividends

We have never declared or paid dividends on our common stock. We do not intend to declare dividends in the foreseeable future because we anticipate that we will reinvest any future earnings into the development and growth of our business. Any decision as to the future payment of dividends will depend on our results of operations and financial position and such other factors as our Board of Directors in its discretion deems relevant.

| 13 |

| --- |

(d)Securities Authorized for Issuance under Equity Compensation Plan

The Company does not have in effect any compensation plans under which the Company’s equity securities are authorized for issuance.

TransferAgent

Our transfer agent is VStock, LLC located at 18 Lafayette Place, Woodmere, NY 11598.

RecentSales of Unregistered Securities

During the years ended July 31, 2019 and 2018, we have not issued any securities which were not registered under the Securities Act and not previously disclosed in the Company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

Rule10B-18 Transactions

During the years ended July 31, 2019 and 2018, there were no repurchases of the Company’s common stock by the Company.

ITEM6. SELECTED FINANCIAL DATA.

Not applicable

ITEM7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

THE FOLLOWING DISCUSSION OF OUR PLAN OF OPERATION AND RESULTS OF OPERATIONS SHOULD BE READ IN CONJUNCTION WITH THE FINANCIAL STATEMENTS AND RELATED NOTES TO THE FINANCIAL STATEMENTS INCLUDED ELSEWHERE IN THIS REPORT. THIS DISCUSSION CONTAINS FORWARD-LOOKING STATEMENTS THAT RELATE TO FUTURE EVENTS OR OUR FUTURE FINANCIAL PERFORMANCE. THESE STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS THAT MAY CAUSE OUR ACTUAL RESULTS, LEVELS OF ACTIVITY, PERFORMANCE OR ACHIEVEMENTS TO BE MATERIALLY DIFFERENT FROM ANY FUTURE RESULTS, LEVELS OF ACTIVITY, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY THESE FORWARD-LOOKING STATEMENTS. THESE RISKS AND OTHER FACTORS INCLUDE, AMONG OTHERS, THOSE LISTED UNDER “FORWARD-LOOKING STATEMENTS” AND “RISK FACTORS” AND THOSE INCLUDED ELSEWHERE IN THIS REPORT.

| 14 |

| --- |

This discussion summarizes the significant factors affecting the consolidated financial statements, financial condition, liquidity, and cash flows of Healthcare Integrated Technologies, Inc, for the fiscal years ended July 31, 2019 and 2018 and the interim periods included herein. The following discussion and analysis should be read in conjunction with the consolidated financial statements and notes included elsewhere in this Form 10-K.

ExecutiveOverview

We are healthcare technology company whose primary operations are through our IndeLiving subsidiary, which we acquired in March 2018. With the acquisition of IndeLiving, our core focus changed, and we discontinued our operations of our Grasshopper Colorado subsidiary in February 2019. We also changed our name to Healthcare Integrated Technologies, Inc., to better reflect our new operations. As a result, our operations, management and board of directors, and our business in general have undergone a substantial change.

Strategy

Our mission is to grow a profitable healthcare technology company through our IndeLiving subsidiary for the long-term benefit of our shareholders by focusing on our relationship with our primary hardware supplier, further development of our proprietary software and developing new uses and product lines for the technology. Our management team is focused on maintaining the financial flexibility and assembling the right complement of personnel and outside consultants required to successfully execute our mission.

Financialand Operating Results

Highlights for fiscal years 2019 and 2018 and the interim periods included in this Form 10-K include:

●	In<br> February 2019, we discontinued our operations of our Grasshopper Colorado subsidiary, which was our only source of revenue.
●	On<br> February 21, 2018, we issued 1,000,000 shares of common stock to Acorn Management Partners, LLC (“Acorn”) in exchange<br> for Acorn forfeiting warrants to purchase 6,000,000 shares of our common stock. The warrants had an exercise price of $0.01<br> and expired ten years from the date of issuance. The transaction terms were negotiated in good faith with an unrelated third<br> party.
●	On<br> March 13, 2018 we entered into a Share Acquisition and Exchange Agreement with IndeLiving<br> Holdings, Inc., a Florida corporation (“IndeLiving”), and its shareholders,<br> under which we acquired 100% of the outstanding capital stock of IndeLiving in exchange<br> for 5,200,000 shares of our common stock. Estimated value of the shares issued was $22,751,<br> which equaled the estimated value of the net assets acquired.
●	On<br> March 13, 2018 (the “Termination Date”) we canceled the three-year consulting and advisory agreement with Platinum<br> Equity Advisors, LLC (the “Platinum Agreement”). Compensation consisted of a monthly retainer fee of $20,000.<br> In addition, for services rendered through January 15, 2016, we issued 8,000,000 shares of our common stock at a value of<br> $0.35 per share, or $2,788,000 (the “Stock Grant”). The value of the Stock Grant was being amortized over the<br> term of the agreement through the Termination Date. For the year ended July 31, 2018, we recorded consulting fees expense<br> of $147,742 for the monthly retainer fee and we recorded stock-based compensation expense of $1,355,278, which included the<br> full unamortized balance of the Stock Grant at the Termination Date. Services under the Platinum Agreement were being performed<br> by Scott M. Boruff, our current CEO.
●	On<br> March 13, 2018, Scott M. Boruff was appointed CEO and entered into a three-year employment agreement with the Company. The<br> employment agreement provides for a base salary of $300,000 per annum, a monthly automobile allowance of $1,950 and 2,500,000<br> options to purchase the Company’s common stock at an exercise price of $3.00 per share and become vested and exercisable<br> in equal annual installments over a period of four (4) years from the grant date. The value of the options on the grant date<br> was estimated using the Black-Scholes pricing model and is being recognized as an expense over the vesting term.
●	On<br> various dates during the month of March 2018 we issued a series of 5% Convertible Promissory Notes (collectively, the “5%<br> Notes”) totaling $750,000 in net proceeds. We incurred no costs related to the issuance of the 5% Notes. The 5% Notes<br> bear interest at the rate of five percent (5%) per annum, compounded annually and matured one-year from the date of issuance.<br> The 5% Notes are currently in default. Management is currently negotiating an amendment to the 5% Notes to extend the maturity<br> dates of the notes. See Note 9 – Debt to the consolidated financial statements for additional information.
●	On<br> August 7, 2019, we secured a contract with a hardware supplier, Vayyar Imaging, Ltd., to produce our monitoring devices. The<br> contract requires us to purchase $2,000,000 in product by July 31, 2020.
●	On<br> October 8, 2019, Charles B. Lobetti, III was appointed CFO and entered into a three-year employment agreement with the Company.<br> The employment agreement provides for a base salary of $52,000 per annum (on a part-time basis), a monthly automobile allowance<br> of $400 and 600,000 options to purchase the Company’s common stock at an exercise price of $0.15 per share with 25%<br> immediately vested and exercisable on the grant date and the remaining options vesting equally over a period of three (3)<br> years from the grant date. The value of the options on the grant date was estimated using the Black-Scholes pricing model<br> and is being recognized as an expense over the vesting term.
●	On<br> February 11, 2020, we completed a private placement of 1,000,000 shares of our common stock at a price of $0.10 per share<br> resulting in net proceeds to the Company of $100,000. We incurred no cost related to the private placement.

| 15 |

| --- |

Resultsof Operations

Revenues

Our only source of revenue was derived from our Grasshopper Colorado subsidiary, the operations of which were discontinued in February 2019. For all consolidated statements of operations included in this Form 10-K after January 31, 2019, the net loss incurred by Grasshopper Colorado is presented separately as discontinued operations.

Loss from discontinued operations consisted of the following at July 31, 2019 and 2018:

	July<br> 31, 2019			July<br> 31, 2018
Net<br> revenue	$	27,909		$	115,614
Operating<br> expenses		(35,969	)		(188,636	)
Interest<br> expense		(7,534	)		(12,368	)
Loss<br> from discontinued operations	$	(15,594	)	$	(85,390	)

An analysis or discussion of our revenues does not provide any useful information since we discontinued the operations of our only revenue source.

Selling,General and Administrative Expenses

The table below presents a comparison of our selling, general and administrative expenses for the years ended July 31, 2019 and 2018:

	July<br> 31, 2019		July<br> 31, 2018
Officer’s<br> salaries	$	336,965	$	134,248
Stock-based<br> compensation		294,510		1,475,979
Advertising,<br> marketing and product demonstration expenses		90,212		56,143
Professional<br> fees		44,129		265,327
Other		18,177		19,960
Total<br> selling, general and administrative expenses	$	783,993	$	1,951,657

Officer’s salaries were $336,965 in fiscal 2019, representing an increase of $212,717 over the fiscal 2018 amount. The increase is directly related to the March 13, 2018 employment agreement with our CEO. Prior to the employment agreement, fees were being earned by Platinum Equity Advisors, LLC, where our CEO served as Chief Manager, and were recorded as professional fees. The net increase in Officer’s salaries is a result of the difference between our current and former CEO’s compensation. Officer’s salaries for the interim periods ending October 31, 2019 and January 31, 2020 also include compensation expense from our CFO’s employment agreement discussed above.

Stock-based compensation decreased $1,181,469 from fiscal 2018. Fiscal 2019 stock-based compensation consisted entirely of the expense related to the stock options granted to our CEO pursuant to the March 13, 2018 employment agreement discussed above. Fiscal 2018 stock-based compensation included the expense related to the stock options granted to our CEO, as well as the normal periodic amortization of the expense related to the 8,000,000 share grant related to the Platinum Agreement discussed above. In addition to the normal periodic amortization, upon termination of the Platinum Agreement on March 13, 2018, we recognized share-based compensation expense for the remaining $890,611 unamortized balance. Stock-based compensation for the interim periods ending October 31, 2019 and January 31, 2020 also include the expense from the granting of stock options under our CFO’s employment agreement discussed above.

Advertising, marketing and product demonstration expenses increased $34,069 over the fiscal 2018 amount primarily due to the acquisition of IndeLiving on March 13, 2018. IndeLiving has and, with adequate capital, will continue to incur substantially more advertising, marketing and product demonstration costs than the Company has previously incurred.

Professional fees decreased $221,198 in fiscal 2019 as compared to fiscal 2018. The decrease is primarily related to the cancellation of the Platinum Agreement and additional legal and accounting fees in fiscal 2018 related to the IndeLiving acquisition (see above).

InterestExpense

Interest expense increased $24,564 for fiscal 2019 as compared to fiscal 2018. All our interest expense is related to the issuance of the 5% Convertible Promissory Notes in March 2018 (see above) and our assumption of a Ford Credit installment note in the IndeLiving acquisition. Accordingly, fiscal 2018 includes approximately three and one-half months of interest on the notes while fiscal 2019 included a full year’s interest expense.

| 16 |

| --- |

Liquidityand Capital Resources

WorkingCapital

The following table summarizes our working capital for the fiscal years ending July 31, 2019 and 2018:

	July<br> 31, 2019			July<br> 31, 2018
Current<br> assets	$	725		$	182,097
Current<br> liabilities		(1,806,413	)		(1,450,794	)
Working<br> capital deficiency	$	(1,805,688	)	$	(1,268,697	)

Current assets for the year ended July 31, 2019 decreased compared to July 31, 2018, primarily due to a decrease in cash and a decrease in accounts receivable upon the discontinuance of the Grasshopper Colorado operations.

Current liabilities for the year ended July 31, 2019 increased compared to July 31, 2018 due to increases in short-term loans from management and accrued but unpaid officer’s compensation.

NetCash Used by Operating Activities

Since we discontinued the operations of our Grasshopper Colorado subsidiary in February 2019, we no longer have a revenue source and will continue to have negative cash flow from operations for the near future. The factors in determining operating cash flows are largely the same as those that affect net earnings, except for non-cash expenses such as depreciation and stock-based compensation, which affect earnings but do not affect cash flow. Net cash used by operating activities was $99,443 for the year ended July 31, 2019 compared to $319,235 for the year ended July 31, 2018. The decrease in cash used during fiscal 2019 is attributable to management adhering to a strict cash expenditure budget until such time as cash can be raised from outside sources.

| 17 |

| --- |

NetCash Provided by Financing Activities

During fiscal year 2019, we raised cash exclusively from short-term loans from management. During fiscal year 2018, we issued a series of 5% Convertible Promissory Notes resulting in $750,000 in net proceeds to the Company in addition to short-term loans of $42,275 from related and third parties. The increases during fiscal 2019 and 2018 were offset by payments for amounts owed to related parties of $75,800 and $310,650 respectively.

At this time, we cannot provide investors with any assurance that we will be able to obtain sufficient funding from debt financing and/or the sale of our equity securities to meet our obligations over the next twelve months. We are likely to continue using short-term loans from management to meet our short-term funding needs. We have no material commitments for capital expenditures as of July 31, 2019.

GoingConcern Qualification

We have a history of losses, an accumulated deficit, a negative working capital and have not generated cash from operations to support a meaningful and ongoing business plan. Our Independent Registered Public Accounting Firm has included a “Going Concern Qualification” in their report for the years ended July 31, 2019, 2018, 2017 and 2016. The foregoing raises substantial doubt about the Company’s ability to continue as a going concern. We intend on financing our future activities and working capital needs largely from the sale of private and/or public equity securities with additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. There is no guarantee that additional capital or debt financing will be available when and to the extent required, or that if available, it will be on terms acceptable to us. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The “Going Concern Qualification” might make it substantially more difficult to raise capital.

CriticalAccounting Policies and Estimates

We believe the following critical policies impact our more significant judgments and estimates used in preparation of our financial statements.

| 18 |

| --- |

We prepare our financial statements in conformity with United States of America generally accepted accounting principles (“GAAP”). These principals require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management believes that these estimates are reasonable and have been discussed with the Board; however, actual results could differ from those estimates.

We issue options and warrants to consultants, directors, and officers as compensation for services. These options and warrants are valued using the Black-Scholes model, which focuses on the current stock price and the volatility of moves to predict the likelihood of future stock moves. This method of valuation is typically used to estimate the value of stock options and warrants based on the price of the underlying stock.

Long-lived assets such as property, equipment and identifiable intangibles are reviewed for impairment whenever facts and circumstances indicate that the carrying value may not be recoverable. When required impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable from its undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. When fair values are not available, we estimate fair value using the expected future cash flows discounted at a rate commensurate with the risk associated with the recovery of the assets. We did not recognize any impairment losses for any periods presented.

Fair value estimates used in preparation of the financial statements are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values. These financial instruments include cash, accounts payable, note payable and due to related parties. Fair values were assumed to approximate carrying values for these financial instruments since they are short-term in nature and their carrying amounts approximate fair values or they are receivable or payable on demand.

| 19 |

| --- |

BusinessCombinations

We account for business combinations under the acquisition method of accounting. The acquisition method requires that the acquired assets and liabilities, including contingencies, be recorded at fair value determined on the acquisition date and that changes thereafter be reflected in income (loss). The estimation of fair values of the assets and liabilities assumed involves several estimates and assumptions that could differ materially from the actual amounts recorded. The results of the acquired businesses are included in our results from operations beginning from the day of acquisition.

RevenueRecognition

We adopted ASC 606 effective January 1, 2018 using the modified retrospective method. Under this method, the Company follows the five-step model provided by ASC Topic 606 in order to recognize revenue in the following manner: 1) Identify the contract; 2) Identify the performance obligations of the contract; 3) Determine the transaction price of the contract; 4) Allocate the transaction price to the performance obligations; and 5) Recognize revenue. An entity recognizes revenue for the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. The Company’s revenue recognition policies remained substantially unchanged as a result of the adoption of ASC 606, and there were no significant changes in business processes or systems.

TemporaryStaffing Revenue

Prior to the discontinuance of its operations in February 2019, Grasshopper Colorado earned revenue by providing specialized temporary staffing solutions to the cannabis industry. We provided temporary labor at an agreed upon rate per hour. Billings were invoiced on a per-hour basis as the temporary staffing services were delivered to the customer. Revenue from the majority of our temporary staffing services were recognized at a point in time. We applied the practical expedient to recognize revenue for these services at various intervals based on the number of hours completed and agreed upon rate per hour at that time.

CapitalResources

We had no material commitments for capital expenditures as of July 31, 2019. Subsequent to July 31, 2019, on August 7, 2019, our wholly owned subsidiary, IndeLiving Holdings, Inc., a Florida corporation (“Inde Living”), as buyer and licensee, and Vayyar Imaging, Ltd. (“Vayyar”), as seller and licensor, entered into a Walabot Home Reseller Agreement, dated as of July 31, 2019 (the “Agreement”). Under the terms of the Agreement, among other things, Inde Living has agreed to purchase from Vayyar Walabot home hardware devices, used in the monitoring of residents and patients under care in assisted living and similar facilities (the “Products”). The Company is required to order a minimum of $2,000,000 in Products by July 31, 2020 (exclusive of shipping costs and taxes).

The agreement also provides, among other terms, Inde Living with a non-exclusive, revocable license to sell the Products within the United States during the term of the Agreement, which has an initial term extending until July 31, 2020 and which automatically extends year-to-year afterwards unless either party elects to terminate the Agreement. The agreement provides a client becomes exclusive when we sell 20 units or more to the client.

Although the Agreement is dated as of July 31, 2019, signature pages were executed and delivered between both parties on August 7, 2019, and so it became legally binding on the parties on that date.

Off-BalanceSheet Arrangements

The Company has no off-balance sheet arrangements as of July 31, 2019 or 2018.

ITEM7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We do not hold any derivative instruments and do not engage in any hedging activities.

ITEM8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

The financial statements and supplementary financial information required to be filed under this Item 8 are presented in Part IV, Item 15 of this Form 10-K and are incorporated herein by reference.

| 20 |

| --- |

ITEM9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

On March 6, 2017, Stevenson & Company CPAs, LLP (“Stevenson”) informed the Company that Stevenson was resigning, effective immediately, as the Company’s independent registered public accounting firm. Stevenson resigned because Stevenson declined to stand for re-appointment.

During the fiscal year ended July 31, 2016 and in the subsequent interim period through March 6, 2017, there were (i) no “disagreements” (as that term is described in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and Stevenson on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Stevenson, would have caused Stevenson to make reference to the subject matter of such disagreements in its reports on the consolidated financial statements for such years, and (ii) no “reportable events” (as that term is described in Item 304(a)(1)(v) of Regulation S-K).

Stevenson’s reports on the consolidated financial statements of the Company for the fiscal years ended July 31, 2015 and 2014 did not contain any adverse opinion or disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles.

On March 7, 2017, the Board of Directors of the Company engaged RBSM, LLP (“RBSM”) as the Company’s new independent registered public accounting firm.

During the fiscal year ended July 31, 2016 and in the subsequent interim periods through March 7, 2017, neither the Company nor anyone acting on its behalf consulted RBSM regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered with respect to the consolidated financial statements of the Company, and neither a written report nor oral advice was provided to the Company by RBSM that RBSM concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue or (ii) any matter that was either the subject of a “disagreement” (as that term is used in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a “reportable event” (as that term is defined in Item 304(a)(1)(v) of Regulation S-K).

On September 13, 2018, the Company dismissed RBSM LLP, effective September 12, 2018, as our independent registered public accounting firm. RBSM LLP audited our financial statements for the fiscal years ended July 31, 2016 and 2017. The dismissal of RBSM LLP was approved by our Board of Directors on September 12, 2018. RBSM LLP did not resign or decline to stand for re-election.

Neither the report of RBSM LLP dated July 18, 2017 on our consolidated balance sheet at July 31, 2016, and the related consolidated statements of operations, changes in stockholders’ deficit, and cash flows for the year ended July 31, 2016 nor the report of RBSM LLP dated November 14, 2017 on our consolidated balance sheets at July 31, 2017 and 2016, and the related consolidated statements of operations, changes in stockholders’ deficit, and cash flows for the years ended July 31, 2017 and 2016 contained an adverse opinion or a disclaimer of opinion, nor was either such report qualified or modified as to uncertainty, audit scope, or accounting principles, other than each such report was qualified as to our ability to continue as going concern.

During the fiscal year ended July 31, 2017 and July 31, 2018 and in the subsequent interim period through September 13, 2018, there were (i) no “disagreements” (as that term is described in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and RBSM on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of RBSM, would have caused RBSM to make reference to the subject matter of such disagreements in its reports on the consolidated financial statements for such years, and (ii) no “reportable events” (as that term is described in Item 304(a)(1)(v) of Regulation S-K).

| 21 |

| --- |

On September 13, 2018, the Company engaged Marcum LLP as our independent registered public accounting firm.

During our two most recent fiscal years and the subsequent interim period prior to retaining Marcum LLP (1) neither we nor anyone on our behalf consulted Marcum LLP regarding (a) either the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on our financial statements or (b) any matter that was the subject of a disagreement or a reportable event as set forth in Item 304(a)(1)(iv) and (v), respectively, of Regulation S-K, and (2) Marcum LLP did not provide us with a written report or oral advice that they concluded was an important factor considered by us in reaching a decision as to accounting, auditing or financial reporting issue.

On January 7, 2020, the Company dismissed Marcum LLP as our independent registered public accounting firm. The dismissal of Marcum LLP was approved by our Board of Directors. Marcum LLP did not resign or decline to stand for re-election.

During the time that Marcum LLP served as our independent registered public accounting firm, we did not timely file financial statements or provide information for Marcum LLP to be able to complete its audit of our financial statements dated July 31, 2018 or July 31, 2019 and the reviews of any interim financial statements for the quarterly periods of those fiscal years. As a result, no report of Marcum LLP contained an adverse opinion or a disclaimer of opinion, or was qualified or modified as to uncertainly, audit scope, or accounting principles, as no reports were filed.

During our two most recent fiscal years and the subsequent interim period preceding our decision to dismiss Marcum LLP we had no disagreements with the firm on any matter of accounting principles or practices, financial statement disclosure, or auditing scope of procedure which disagreement if not resolved to the satisfaction of Marcum LLP would have caused it to make reference to the subject matter of the disagreement in connection with its report.

On January 7, 2020, the Company engaged Rodefer Moss & Co. PLLC as our independent registered public accounting firm.

During our two most recent fiscal years and the subsequent interim period prior to retaining Rodefer Moss & Co. PLLC (1) neither we nor anyone on our behalf consulted Rodefer Moss & Co. PLLC regarding (a) either the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on our financial statements or (b) any matter that was the subject of a disagreement or a reportable event as set forth in Item 304(a)(1)(iv) and (v), respectively, of Regulation S-K, and (2) Rodefer Moss & Co. PLLC did not provide us with a written report or oral advice that they concluded was an important factor considered by us in reaching a decision as to accounting, auditing or financial reporting issue.

ITEM9A. CONTROLS AND PROCEDURES.

DisclosureControls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) under the Securities Exchange Act of 1934, as amended, at the end of the period covered by this report (the “Evaluation Date”). In conducting its evaluation, management considered the material weaknesses described below in Management’s Report on Internal Control over Financial Reporting.

Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of the Evaluation Date we did not maintain disclosure controls and procedures that were effective in providing reasonable assurances that information required to be disclosed in our reports filed under the Securities Exchange act of 1934 was recorded, processed, summarized and reported within the time periods prescribed by SEC rules and regulations, and that such information was accumulated and communicated to our management to allow timely decisions regarding required disclosure.

Our management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

| 22 |

| --- |

Management’sReport on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Our management assessed the effectiveness of our internal control over financial reporting as of July 31, 2019. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of July 31, 2019 our internal controls over financial reporting were not effective.

In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework. Our management has concluded that, as of July 31, 2019, our internal control over financial reporting is not effective based on these criteria. Material weaknesses noted by our management include:

●	Lack<br> of a functioning audit committee;
●	Lack<br> of a majority of outside directors on our board of directors, resulting in ineffective oversight in the establishment and<br> monitoring of required internal controls and procedures;
●	Inadequate<br> segregation of duties consistent with control objectives and affecting the functions of authorization, recordkeeping, custody<br> of assets, and reconciliation;
●	Management<br> dominated by a single individual/small group without adequate compensating controls.

This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the SEC that permit us to provide only management’s report in this annual report.”

Changesin Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed fiscal year that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM9B. OTHER INFORMATION

None.

| 23 |

| --- |

PARTIII

ITEM10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

The following table sets forth information concerning our officers and directors as of the dates indicated. The directors of the Company serve until their successors are elected and shall qualify. Executive officers are elected by the Board of Directors and serve at the discretion of the directors.

Priorto March 13, 2018

Name	Age	Title
Melanie<br> Osterman	64	President,<br> Chief Executive Officer and Chief Financial Officer
Jeremy<br> Gindro	27	Director

Set forth below is a brief description of the background and business experience of each of the executive officers and directors indicated above.

MelanieOsterman, President, Chief Executive Officer and Chief Financial Officer, age 64

Ms. Osterman has over 20 years of management experience in multiple fields of employment. From 2005 until her appointment as President, Chief Executive Officer and Chief Financial Officer in May 2015, Ms. Osterman was business development director for Security Title Insurance, where she was responsible for all aspects of customer relations and training employees on regulations in the insurance industry. Prior to that position, she served as marketing and business development for Pueblo Bank & Trust.

JeremyGindro, Director, age 27

Mr. Gindro was the sole Director of the Company. From September 1, 2005 through March 13, 2018, Mr. Gindro has been a big game guide for individuals and groups of hunters. From May 2008 through present, Mr. Gindro is employed as a Supervisor working for Jim Gindro Construction, Pueblo, Colorado. His responsibilities include operating heavy machinery including back hoes and bobcats to dig foundations for new homes, septic tanks, and underground utilities lines and piping for new and existing homes. Mr. Gindro was instrumental in procuring new business for the Company during his tenure and supervising all phases of the rough build-out of single-family structures for his family business.

AfterMarch 13, 2018

Name	Age	Title
Scott<br> M. Boruff	56	Chief Executive<br> Officer, Director
Charles<br> B. Lobetti, III	57	Chief<br> Financial Officer

Set forth below is a brief description of the background and business experience of each of our current executive officers and directors.

| 24 |

| --- |

ScottM. Boruff, Chief Executive Officer, Director, age 56

Mr. Boruff has served as our Chief Executive Officer and Sole Director since March 13, 2018. He has been the sole officer and director of IndeLiving Holdings, Inc. since the company’s formation in 2016. He has also served as the Manager of Platinum Equity Advisors, LLC (“Platinum Equity”) since its formation in 2016. In addition to providing consulting and advisory services, Platinum Equity has interests in a real estate brokerage firm and a luxury real estate auction firm. Mr. Boruff is a proven executive with a diverse business background in investment banking and real estate development. He currently serves as Manager of Own Shares, LLC, a privately held holding company with interests in various entertainment ventures, and Managing Member of Stonewalk Companies, privately held real estate development company. As a professional in investment banking, he specialized in consulting services and strategic planning with an emphasis on companies in the oil and gas field. Mr. Boruff served as a member of the Board of Directors of Miller Energy Resources, Inc., a publicly traded company, from August 2008 until March 2016, serving as Executive Chairman of the Board of Directors from September 2014 until March 2016 and Chief Executive Officer from August 2008 to September 2014. In October 2015, when it was being led by a successor management team, Miller Energy Resources, Inc. filed a voluntary petition for reorganization under chapter 11 of title 11 of the U.S. Code in a pre-packaged bankruptcy. It remained a debtor in possession and emerged from bankruptcy in March 2016. Mr. Boruff was a director and 49% owner of Dimirak Securities Corporation, a broker-dealer and member of FINRA, from April 2009 until July 2012. In July 2012, Mr. Boruff sold his interest in Dimirak. He has more than 30 years of experience in developing commercial real estate projects and from 2006 to 2007 Mr. Boruff successfully led transactions averaging $150 to $200 million in size while serving as a director of Cresta Capital Strategies, LLC. Mr. Boruff received a Bachelor of Science degree in Business Administration from East Tennessee State University.

CharlesB. Lobetti, III, Chief Financial Officer, Age 57

Mr. Lobetti has served as our Chief Financial Officer since October 8, 2019. He holds both Bachelor of Science in Business Administration (1985) and Master of Accountancy (1986) degrees from the University of Tennessee and is a licensed Certified Public Accountant (Inactive) in the State of Tennessee. Upon graduation, Mr. Lobetti accepted a position in the tax department of the Tampa, Florida office of Ernst & Young where he progressed to Senior Tax Consultant before he left the firm in 1989 to return to his hometown of Knoxville, Tennessee as the Tax Manager with a progressive, local accounting firm. In 1990, Mr. Lobetti, along with two co-workers, formed the accounting firm of Lobetti, Ideker & Reel (“LIR”) where he served as President and Director of Tax Services. LIR was a member of the AICPA’s SEC Practice Section and served several SEC registrant clients. In 1998, Mr. Lobetti left LIR to accept a position of Chief Financial Officer of United Petroleum Corporation (“UPET”), a small cap, SEC registrant oil and natural gas development company and convenience store operator. Following his tenure at UPET, Mr. Lobetti serviced as Chief Financial Officer for boutique investment banking/private equity firm specializing in the placement and funding of Regulation D and Regulation S offerings. He spent the next 10-years working in various investment banking, commercial mortgage banking and commercial banking functions before accepting the position of Controller – Alaska Operations with Miller Energy Resources, Inc.(“Miller”), and SEC registrant oil and gas exploration and production company. Shortly after accepting the position in 2011, Mr. Lobetti was promoted to Corporate Controller and thereafter appointed Treasurer in 2012. Since leaving Miller in 2014, Mr. Lobetti enjoyed spending time with his family and working part-time in commercial mortgage banking until recently accepting the position of Chief Financial Officer of Healthcare Integrated Resources, Inc.

| 25 |

| --- |

FamilyRelationships

There are no family relationships among any of our directors or executive officers.

Involvementin Certain Legal Proceedings

To the best of the Company’s knowledge, none of the Company’s directors or executive officers has, during the past ten years, except as set forth below:

●	been<br> convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other<br> minor offenses);
●	had<br> any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or<br> business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or<br> within two years prior to that time;
●	been<br> the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent<br> jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting,<br> his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance<br> activities, or to be associated with persons engaged in any such activity;
●	been<br> found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to<br> have violated a federal or state securities or commodities law, and the judgment in such civil action has not been reversed,<br> suspended, or vacated;
●	been<br> the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently<br> reversed, suspended or vacated, relating to (i) an alleged violation of any federal or state securities or commodities law<br> or regulation, (ii) any law or regulation respecting financial institutions or insurance companies including, but not limited<br> to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent<br> cease-and-desist order, or removal or prohibition order, or (iii) any law or regulation prohibiting mail or wire fraud or<br> fraud in connection with any business entity; or
●	been<br> the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory<br> organization (as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of<br> the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority<br> over its members or persons associated with a member.

Mr. Boruff served as a member of the Board of Directors, as Chief Executive Officer, and as Executive Chairman of Miller Energy Resources, Inc. during the two years preceding Miller Energy Resources, Inc.’s filing of a bankruptcy petition in August 2015.

Mr. Lobetti served as Treasurer of Miller Energy Resources, Inc. during the two-year period preceding Miller Energy Resources, Inc.’s filing of a bankruptcy petition in August 2015.

| 26 |

| --- |

Except as set forth in the Company’s discussion below in “Certain Relationships and Related Transactions, and Director Independence”, none of the Company’s directors or executive officers has been involved in any transactions with the Company or any of the Company’s directors, executive officers, affiliates, or associates which are required to be disclosed pursuant to the rules and regulations of the Commission.

Compliancewith Section 16(A) of the Exchange Act

Section 16(a) of the Exchange Act requires the Company’s directors, executive officers and persons who beneficially own 10% or more of a class of securities registered under Section 12 of the Exchange Act to file reports of beneficial ownership and changes in beneficial ownership with the SEC. Directors, executive officers and greater than 10% stockholders are required by the rules and regulations of the SEC to furnish the Company with copies of all reports filed by them in compliance with Section 16(a).

Based solely on our review of certain reports filed with the Securities and Exchange Commission pursuant to Section 16(a) of the Securities Exchange Act of 1934, as amended, the reports required to be filed with respect to transactions in our common stock during the fiscal year ended July 31, 2019 and 2018, were not timely.

Termof Office

The Company’s directors are elected by the Company’s stockholders for a one-year term until the next annual general meeting of the Company’s stockholders, or until removed by the stockholders in accordance with the Company’s bylaws. The Company’s officers are appointed by the Board and hold office until removed by the Board.

Codeof Ethics

The Company does not currently have a code of ethics, and because the Company has only limited business operations and only two officers and one director, the Company believes that a code of ethics would have limited utility. The Company intends to adopt such a code of ethics as the Company’s business operations expand and the Company has more employees.

BoardCommittees

As we only have one board member and given our limited operations, we do not have separate or independent audit or compensation committees. Our Board of Directors has determined that it does not have an “audit committee financial expert,” as that term is defined in Item 407(d)(5) of Regulation S-K. In addition, we have not adopted any procedures by which our shareholders may recommend nominees to our Board of Directors.

| 27 |

| --- |

ITEM11. EXECUTIVE COMPENSATION.

The following table summarizes all compensation recorded by us in the past two years for:

●	our<br> principal executive officer or other individual serving in a similar capacity,
●	our<br> two most highly compensated executive officers other than our principal executive officer who were serving as executive officers<br> at July 31, 2019 and July 31, 2018 as that term is defined under Rule B-7 of the Securities Exchange Act of 1934, and
●	up<br> to two additional individuals for whom disclosure would have been required but for the fact that the individual was not serving<br> as an executive officer at July 31, 2019 and July 31, 2018.

SummaryCompensation Table (in dollars)

Name and Principal	Fiscal	****		****		Stock		Non-Equity<br><br> <br>Incentive Plan		Non-Qualified Deferred Compensation		All Other		****
Position	Year	Salary		Bonus		Awards		Compensation		Earnings		Compensation		Total
Scott<br> B. Boruff	2019		300,000		-		294,510		-		-		23,400		617,910
Chief<br> Executive Officer	2018		115,323		-		120,701		-		-		8,995		245,019
Director<br> (1)
Charles<br> B. Lobetti, III	2019		-		-		-		-		-		-		-
Chief<br> Financial Officer (2)	2018		-		-		-		-		-		-		-
Melanie<br> Osterman	2019		38,900		-		-		-		-		-		38,900
Chief<br> Executive Officer	2018		16,500		-		-		-		-		-		16,500
Chief<br> Financial Officer (3)
Jeremy<br> Gindro	2019		-		-		-		-		-		-		-
Director<br> (4)	2018		-		-		-		-		-		-		-
1)	Mr.<br> Boruff has served as our Chief Executive Officer and our sole Director since March 13, 2018.
---	---
2)	Mr.<br> Lobetti has served as our Chief Financial Officer since October 8, 2019, which is after the end of our fiscal year July 31,<br> 2019 but included in the interim periods October 31, 2019 and January 31, 2020.
3)	Ms.<br> Osterman served as our Chief Executive Officer and Chief Financial Officer from May 2015 to March 13, 2018.
4)	Mr.<br> Gindro served on our Board of Directors through March 13, 2018.

DirectorCompensation

We do not currently pay any cash fees to our directors, nor do we pay director’s expenses in attending board meetings.

ExecutiveEmployment Agreements

Scott M. Boruff and the Company entered into an Employment Agreement dated March 13, 2018, in which Mr. Boruff agreed to serve as our Chief Executive Officer. As compensation, we agreed to pay him an annual salary of $300,000 and he is entitled to discretionary bonuses as may be awarded from time to time by our Board of Directors. As additional compensation we granted him an option to purchase 2,500,000 shares of the Company’s common stock at an exercise price of $3.00 per share, which exceeded the fair market price of our common stock on the date of grant, vesting in four equal annual installments commencing on the grant date. The vesting date of any unvested options accelerates in the event of a Change in Control (as defined in the Employment Agreement). Mr. Boruff is also entitled to paid vacation and sick leave, an automobile allowance and participation in any employee benefit plans or programs we may offer. The initial term of the Employment Agreement will automatically renew for an additional one-year term unless either party provides notice of non-renewal.

The Employment Agreement terminates upon the death or disability of Mr. Boruff, and may be terminated by us for cause, or by Mr. Boruff without cause or for good reason. If the Employment Agreement is terminated for by us for cause, upon his death or disability, at non-renewal or by Mr. Boruff without good cause, he is only entitled to receive compensation through the date of termination. If the Employment Agreement is terminated by us without cause or by Mr. Boruff for good reason, we are obligated to pay him severance equal to one year’s base salary and any unpaid incentive compensation. In addition, if at any time during the term of the Employment Agreement Mr. Boruff’s employment is terminated by us without cause within two years after a Change in Control of our company, or in the 90 days prior the Change in Control at the request of the acquiror, we are obligated to pay him an amount equal to 2.99 times his annualized compensation. “Change in Control” is defined in the Employment Agreement to mean the acquisition by any person of beneficial ownership of our securities representing greater than 50% of the combined voting power of our then outstanding voting securities. The Employment Agreement contains customary invention assignment, non-compete and non-solicitation provisions.

Charles B. Lobetti, III and the Company entered into a three-year Employment Agreement dated October 8, 2019, in which Mr. Lobetti agreed to serve as our Chief Financial Officer. As compensation, we agreed to pay him an annual salary of $52,000 and he is entitled to discretionary bonuses as may be awarded from time to time by our Board of Directors. As additional compensation we granted him stock options to purchase 600,000 shares of our common stock at an exercise price of $0.15 per share, which was the closing price of common stock as reported on the OTC Markets on the date immediately preceding the date of this Agreement. The options vested 25% immediately upon exercise of the employment agreement with the remaining vesting equally in annual installments over three (3) years. The vesting date of any unvested options accelerates in the event of a Change in Control (as defined in the Employment Agreement). Mr. Lobetti is also entitled to paid vacation and sick leave, an automobile allowance and participation in any employee benefit plans or programs we may offer. The initial term of the Employment Agreement will automatically renew for an additional one-year term unless either party provides notice of non-renewal.

The Employment Agreement terminates upon the death or disability of Mr. Lobetti, and may be terminated by us for cause, or by Mr. Lobetti for any reason. If the Employment Agreement is terminated for by us for cause, upon his death or disability, at non-renewal or by Mr. Lobetti, he is only entitled to receive base salary accrued but not paid through the date of termination, and in the case of termination due to death or disability, a pro rata payment of the annual incentive earned for the year of termination. If the Employment Agreement is terminated by us without cause or by Mr. Lobetti for good reason, we are obligated to pay him severance equal to one year’s base salary and any unpaid incentive compensation. In addition, if at any time during the term of the Employment Agreement Mr. Lobetti’s employment is terminated by us without cause within two years after a Change in Control of our company, or in the 90 days prior the Change in Control at the request of the acquiror, we are obligated to pay him an amount equal to 2.99 times his annualized compensation. “Change in Control” is defined in the Employment Agreement to mean the acquisition by any person of beneficial ownership of our securities representing greater than 50% of the combined voting power of our then outstanding voting securities. The Employment Agreement contains customary invention assignment, non-compete and non-solicitation provisions.

Melanie Osterman and the Company entered into an Employment Agreement dated May 8, 2015, in which Ms. Osterman received 850,000 shares of the Company’s common stock in return for the performance of duties as Chief Executive Officer and Chief Financial Officer. Ms. Osterman resigned as our Chief Executive Officer on March 13, 2018.

| 28 |

| --- |

ITEM12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

The following table sets forth certain information as of March 18, 2020 regarding the number and percentage of our Common Stock (being our only voting securities) beneficially owned by each officer, director, each person (including any “group” as that term is used in Section 13(d)(3) of the Exchange Act) known by us to own 5% or more of our Common Stock, and all officers and directors as a group.

Title<br> of Class	Name, Title and Address of<br> <br>Beneficial Owner of Shares	Amount of<br> <br>Beneficial<br> <br>Ownership (4)		Percent of<br> <br>Class (5)
Common	Scott<br> M. Boruff, CEO, Director (1)		12,914,854		37.02	%
	1462<br> Rudder Lane
	Knoxville,<br> TN 37919
Common	Charles<br> B. Lobetti, III, CFO (2)		150,000		<1	%
	814<br> Evolve Way
	Knoxville,<br> TN 37915
	All<br> Officers and Directors as a Group		13,064,854		37.45	%
Principal<br> Shareholders:
---	---	---	---	---
Common<br> Stock	Acorn<br> Management Partners, LLC <br> 4080 McGinnis Ferry Rd #101 <br> Alpharetta, GA 30005	2,375,000	6.81	%
	Jeremy<br> Gindro (3)
Common<br> Stock	310<br> Tanner Avenue <br> Florence, CO 81226	7,870,000	22.56	%
1)	The<br> shares owed by Mr. Boruff includes 11,664,854 shares owned by Platinum Equity Advisors, LLC, of which Mr. Boruff is the Chief<br> Manager. Pursuant to Mr. Boruff’s March 13, 2018 employment agreement as our Chief Executive Officer, the shares also<br> include options to purchase 1,250,000 shares of our common stock, which are vested and exercisable at $3.00 per share and<br> expire in 2023. The number of shares owned by Mr. Boruff excludes options to purchase 1,250,000 shares of our common stock<br> at $3.00 per share which have not yet vested and expire in 2023.
---	---
2)	Mr.<br> Lobetti owned no shares at July 31, 2019 and 2018. As of October 8, 2019, Mr. Lobetti’s employment agreement includes<br> an option to purchase 150,000 shares of our common stock which are vested and exercisable at $0.15 per share on such date<br> and expire in 2024. The remaining 450,000 options which will vest annually in equal amounts over a three-year period.
3)	The<br> total includes 100,000 shares owned by James Gindro, the father of Jeremy Gindro.
4)	As<br> used in this table, “beneficial ownership” means the sole or shared power to vote, or to direct the voting of,<br> a security, or the sole or share investment power with respect to a security (i.e., the power to dispose of, or to direct<br> the disposition of a security). The inclusion of any shares as deemed beneficially owned does not constitute an admission<br> of beneficial ownership by the named stockholder.
5)	Unless<br> otherwise indicated, we have been advised that all individuals or entities listed have<br> the sole power to vote and dispose of the number of shares set forth opposite their names.<br> For purposes of computing the number and percentage of shares beneficially owned by a<br> security holder, any shares which such person has the right to acquire within 60 days<br> of March 18, 2020 are deemed to be outstanding, but those shares are not deemed to be<br> outstanding for the purpose of computing the percentage ownership of any other security<br> holder. We currently do not maintain any equity compensation plans. As of March 18, 2020,<br> there were 34,887,500 shares beneficially owned.

| 29 |

| --- |

Changesin Control

We are not aware of any arrangements that may result in “changes in control” as that term is defined by the provisions of Item 403(c) of Regulation S-K.

ITEM13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

Other than compensation arrangements, the following is a description of transactions to which we were a participant or will be a participant to, in which:

●	the<br> amounts involved exceeded or will exceed the lesser of 1% of our total assets or $120,000; and
●	any<br> of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family<br> of the foregoing persons, had or will have a direct or indirect material interest.

To continue operations and meet operating cash requirements, we have periodically relied on advances from related parties, primarily shareholders, until such time as our cash flow from operations meets our cash requirements or we are able to obtain adequate financing through sales of our equity securities and/or traditional debt financing. There is no formal written commitment for continued support by shareholders. Amounts advanced primarily relate to amounts paid to vendors. The advances are considered temporary in nature and have not been formalized by any written agreement. As of July 31, 2019, and July 31, 2018, related parties have advanced the Company $203,581 and $192,426, respectively. The advances are payable on demand and carry no interest.

In addition, we have accrued expenses related to the January 15, 2016 consulting and advisory agreement with Platinum Equity Advisors, LLC (the “Platinum Agreement”), a related party. The Platinum Agreement was terminated by on March 12, 2018 (the “Termination Date”) when Scott M. Boruff, the Chief Manager of Platinum, was appointed Chief Executive Officer of the Company. As of July 31, 2019 and 2018, the accrued amount owed under the Platinum Agreement is $138,216 and $181,833, respectively.

The Platinum Agreement was a three-year consulting and advisory agreement. Compensation consisted of a monthly retainer fee of $20,000. In addition, for services rendered through January 15, 2016, we issued 8,000,000 shares of our common stock at a value of $0.35 per share, or $2,788,000 (the “Stock Grant”). The value of the Stock Grant was being amortized over the term of the agreement through the Termination Date. For the year ended July 31, 2018, we recorded consulting fees expense of $147,742 for the monthly retainer fee and we recorded stock-based compensation expense of $1,355,278, which included the full unamortized balance of the Stock Grant at the Termination Date.

The amounts and terms of the above transactions may not necessarily be indicative of the amounts and terms that would have been incurred had comparable transactions been entered into with independent third parties.

| 30 |

| --- |

DirectorIndependence

We currently have no independent directors. Because our common stock is not currently listed on a national securities exchange, we have used the definition of “independence” of The NASDAQ Stock Market to make this determination. NASDAQ Listing Rule 5605(a)(2) provides that an “independent director” is a person other than an officer or employee of the company or any other individual having a relationship that, in the opinion of the company’s board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The NASDAQ listing rules provide that a director cannot be considered independent if:

●	the<br> director is, or at any time during the past three years was, an employee of the Company;
●	the<br> director or a family member of the director accepted any compensation from the Company in excess of $120,000 during any period<br> of 12 consecutive months within the three years preceding the independence determination (subject to certain exclusions, including,<br> among other things, compensation for board or board committee service);
●	a<br> family member of the director is, or at any time during the past three years was, an executive officer of the Company;
●	the<br> director or a family member of the director is a partner in, controlling stockholder of, or an executive officer of an entity<br> to which the Company made, or from which the Company received, payments in the current or any of the past three fiscal years<br> that exceed 5% of the recipient’s consolidated gross revenue for that year or $200,000, whichever is greater (subject<br> to certain exclusions);
●	the<br> director or a family member of the director is employed as an executive officer of an entity where, at any time during the<br> past three years, any of the executive officers of the Company served on the compensation committee of such other entity;<br> or
●	The<br> director or a family member of the director is a current partner of the Company’s outside auditor, or at any time during<br> the past three years was a partner or employee of the Company’s outside auditor, and who worked on the Company’s<br> audit.

The Company does not currently have a separately designated audit, nominating, or compensation committee.

ITEM14. PRINCIPAL ACCOUNTING FEES AND SERVICES.

The following table sets forth the aggregate fees billed for each of the last two fiscal years for professional services rendered by the principal accountant for the audit of the Company’s annual financial statements and review of financial statements included in the Company’s quarterly reports or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for those fiscal years.

	July<br> 31, 2019		July<br> 31, 2018
Audit<br> Fees	$	-	$	43,007
Audit-Related<br> Fees		22,950		-
Tax<br> Fees		-		-
All<br> Other Fees		-		-
Total	$	22,950	$	43,007

AuditCommittee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors

Given the small size of our Board as well as the limited activities of our Company, our Board of Directors acts as our Audit Committee. Our Board pre-approves all audit and permissible non-audit services. These services may include audit services, audit-related services, tax services, and other services. Our Board approves these services on a case-by-case basis.

| 31 |

| --- |

PARTIV

ITEM15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

Exhibit<br><br> <br>No.	Description
2.1	Business<br> Acquisition Agreement between Tomichi Creek Outfitters and Grasshopper Staffing, Inc., dated March 2, 2015 (as filed by the<br> Company with the Securities and Exchange Commission on Form 8-K dated March 5, 2015 and incorporated herein by reference)
3.1	Articles<br> of Incorporation (as filed by the Company with the Securities and Exchange Commission of Form S-1 dated August 20, 2013, and<br> incorporated herein by reference)
3.2	Certificate<br> of Amendment to Articles of Incorporation, filed November 2, 2015 (as filed with the Securities and Exchange Commission on<br> Form 10-K dated November 23, 2016 and incorporated herein by reference)
3.3	Bylaws<br> (as filed by the Company with the Securities and Exchange Commission of Form S-1 dated August 20, 2013, and incorporated herein<br> by reference)
10.1	Advisory<br> Agreement dated January 15,2016 by and between Grasshopper Staffing, Inc. and Platinum Equity Advisors, LLC (as filed by the<br> Company with the Securities and Exchange Commission on Form 8-K dated January 22, 2016 and incorporated herein by reference)
10.2**	Employment<br> Agreement between the Company and Melanie Osterman, dated May 8, 2015 (as filed with the Securities and Exchange Commission<br> on Form 10-K dated November 23, 2016 and incorporated herein by reference)
10.3**	Employment<br> Agreement between the Company and Scott M. Boruff, dated March13, 2018 (as filed with<br> the Securities and Exchange Commission on Form 8-K dated March 15, 2018 and incorporated<br> herein by reference)
10.4	Walabot<br> Home Reseller Agreement, dated as of July 31, 2019 (as filed with the Securities and<br> Exchange Commission on Form 8-K dated August 12, 2019 and incorporated herein by reference)
10.5**	Employment<br> Agreement between the Company and Charles B. Lobetti, III, dated October 8, 2019 (as<br> filed with the Securities and Exchange Commission on Form 8-K dated January 14, 2020<br> and incorporated herein by reference)
31.1*	Chief<br> Executive Officer and Chief Financial Officer Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002*
32.1*	Chief<br> Financial Officer Certification pursuant to section 906 of the Sarbanes-Oxley Act of 2002*
101.INS*	XBRL<br> Instance Document*
101.SCH*	XBRL<br> Taxonomy Extension Schema Document*
101.CAL*	XBRL<br> Taxonomy Extension Calculation Linkbase Document*
101.DEF*	XBRL<br> Taxonomy Extension Definition Linkbase Document*
101.LAB*	XBRL<br> Taxonomy Extension Label Linkbase Document*
101.PRE*	XBRL<br> Taxonomy Extension Presentation Linkbase Document*

* Filed herewith

** Executive Compensation Agreement

| 32 |

| --- |

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Healthcare<br> Integrated Technologies, Inc.
Date:<br> March 20, 2020
	By:	/s/ Scott M. Boruff
		Scott<br> M. Boruff<br><br> <br>President,<br> Chief Executive Officer (Principal Executive Officer)
	Healthcare<br> Integrated Technologies, Inc.
---	---	---
Date:<br> March 20, 2020
	By:	/s/ Charles B. Lobetti, III
		Charles<br> B. Lobetti, III
		Chief<br> Financial Officer (Principal Financial Officer)

In accordance with the Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Date:<br> March 20, 2020	By:	/s/ Scott M. Boruff
		Scott<br> M. Boruff<br><br> <br>President,<br> Chief Executive Officer, Director (Principal Executive Officer)
Date:<br> March 20, 2020	By:	/s/ Charles B. Lobetti, III
---	---	---
		Charles<br> B. Lobetti, III
		Chief<br> Financial Officer (Principal Financial Officer)

| 33 |

| --- |

INDEXTO FINANCIAL STATEMENTS

	Page
Fiscal Years Ended July 31, 2019 and 2018
Report<br> of Independent Registered Public Accounting Firm	F-1
Consolidated<br> Balance Sheets	F-2
Consolidated<br> Statements of Operations	F-3
Consolidated<br> Statements of Changes in Stockholders’ Deficit	F-4
Consolidated<br> Statements of Cash Flows	F-5
Notes<br> to Consolidated Financial Statements	F-6<br> - F-13

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of

Healthcare Integrated Technologies, Inc.

Opinionon the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Healthcare Integrated Technologies, Inc. (the “Company”) as of July 31, 2019 and 2018, and the related consolidated statements of operations, stockholders’ deficit and cash flows for each of the years in the two-year period ended July 31, 2019 and the related notes. In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of July 31, 2019 and 2018, and the results of its consolidated operations and its consolidated cash flows for each of the years in the two-year period ended July 31, 2019, in conformity with accounting principles generally accepted in the United States of America.

Basisfor Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

SubstantialDoubt about the Company’s Ability to Continue as a Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has a history of losses, an accumulated deficit, has negative working capital and has not generated cash from operations to support a meaningful and ongoing business plan. Management’s evaluation of the events and conditions and management’s plans regarding those matters also are described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to that matter.

/s/Rodefer Moss & Co, PLLC

We have served as the Company’s auditor since 2019

Nashville, Tennessee

March 20, 2020

| F-1 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

CONSOLIDATEDBALANCE SHEETS

			July<br> 31, 2018
ASSETS
CURRENT<br> ASSETS
Cash<br> and cash equivalents	725		$	166,922
Accounts<br> receivable, net	-			14,527
Prepaid<br> expenses and other current assets	-			648
Total<br> current assets	725			182,097
Property<br> and equipment, net	18,392			28,009
Total<br> assets	19,117		$	210,106
LIABILITIES<br> AND STOCKHOLDERS’ DEFICIT
CURRENT<br> LIABILITIES:
Accounts<br> payable and accrued expenses	220,328		$	158,402
Accounts<br> payable and accrued expenses, related party	341,798			374,260
Payroll<br> related liabilities	472,078			146,414
Convertible<br> notes	750,000			750,000
Current<br> portion of long-term debt	3,209			2,718
Total<br> current liabilities	1,787,413			1,431,794
OTHER<br> LIABILITIES:
Long-term<br> debt	2,625			5,225
Total<br> liabilities	1,790,038			1,437,019
STOCKHOLDERS’<br> DEFICIT:
Common<br> stock par value 0.001; 200,000,000 shares authorized; 32,487,500 and 32,487,500 shares issued and outstanding as of July<br> 31, 2019 and July 31, 2018, respectively	32,488			32,488
Additional<br> paid-in capital	8,582,166			8,287,656
Accumulated<br> deficit	(10,385,575	)		(9,547,057	)
Total<br> stockholders’ deficit	(1,770,921	)		(1,226,913	)
Total<br> liabilities and stockholders’ deficit	19,117		$	210,106

All values are in US Dollars.

Seeaccompanying notes to the consolidated financial statements.

| F-2 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

CONSOLIDATEDSTATEMENTS OF OPERATIONS

	For<br> the Years Ended July 31,
	2019			2018
NET<br> REVENUES:
Contract<br> staffing services	$	-		$	-
Direct<br> cost of services		-			-
Gross<br> margin		-			-
OPERATING<br> EXPENSES:
Selling,<br> general and administrative		783,993			1,951,657
Total<br> operating expense		783,993			1,951,657
OPERATING<br> LOSS		(783,993	)		(1,951,657	)
OTHER<br> EXPENSE:
Interest<br> expense		(38,931	)		(14,366	)
Total<br> other expense		(38,931	)		(14,366	)
LOSS<br> FROM CONTINUING OPERATIONS		(822,924	)		(1,966,023	)
					-
LOSS<br> FROM DISCONTINUED OPERATIONS		(15,594	)		(85,390	)
NET<br> LOSS	$	(838,518	)	$	(2,051,413	)
NET LOSS<br> PER COMMON SHARE
Basic<br> and diluted	$	(0.03	)	$	(0.07	)
WEIGHTED<br> AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Basic<br> and diluted		32,487,500			27,833,365

Seeaccompanying notes to the consolidated financial statements.

| F-3 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

STATEMENTSOF CHANGES IN STOCKHOLDERS’ DEFICIT

FORTHE YEARS ENDED JULY 31, 2019 AND 2018

					Additional						Total
	Common<br> Stock				Paid-In			Accumulated			Stockholders’
	Shares		Amount		Capital			Deficit			Deficit
Balance<br> July 31, 2017		26,287,500	$	26,288	$	6,795,126		$	(7,495,644	)	$	(674,230	)
Net<br> loss									(2,051,413	)		(2,051,413	)
Exchange<br> of common stock for warrants		1,000,000		1,000		(1,000	)					-
Acquisition<br> of subsidiary		5,200,000		5,200		17,551						22,751
Stock-based<br> compensation						1,475,979						1,475,979
Balance<br> July 31, 2018		32,487,500		32,488		8,287,656			(9,547,057	)		(1,226,913	)
Net<br> loss									(838,518	)		(838,518	)
Stock-based<br> compensation						294,510						294,510
Balance<br> July 31, 2019		32,487,500	$	32,488	$	8,582,166		$	(10,385,575	)	$	(1,770,921	)

Seeaccompanying notes to the consolidated financial statements.

| F-4 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

CONSOLIDATEDSTATEMENTS OF CASH FLOWS

	For<br> the Years Ended July 31,
	2019			2018
CASH<br> FLOWS FROM OPERATING ACTIVITIES
Net<br> loss	$	(838,518	)	$	(2,051,413	)
Adjustments<br> to reconcile loss to net cash used in operating activities:
Depreciation<br> and amortization		9,617			3,965
Provision<br> for doubtful accounts		-			11,965
Stock-based<br> compensation		294,510			1,475,979
Changes<br> in operating assets and liabilities (excluding effects of acquisitions):
Accounts<br> receivable, net		14,527			16,458
Prepaid<br> expenses and other current assets		648			152
Accounts<br> payable and accrued expenses		61,926			8,174
Accounts<br> payable and accrued expenses, related party		32,183			147,741
Payroll<br> related liabilities		325,664			67,744
NET<br> CASH USED BY OPERATING ACTIVITIES		(99,443	)		(319,235	)
CASH<br> FLOWS FROM INVESTING ACTIVITIES
Cash<br> acquired from acquisition of subsidiary		-			3,960
Purchase<br> of property and equipment		-			(3,275	)
NET<br> CASH PROVIDED BY INVESTING ACTIVITIES		-			685
CASH<br> FLOWS FROM FINANCING ACTIVITIES
Proceeds<br> from issuance of convertible notes		-			750,000
Proceeds<br> from stock issuances		-			2,000
Principal<br> payments of long-term debt		(2,109	)		(718	)
Proceeds<br> from third party loans		-			32,925
Proceeds<br> from related party loans		11,155			9,350
Payments<br> of amounts owed to related parties		(75,800	)		(310,650	)
NET<br> CASH PROVIDED BY FINANCING ACTIVITIES		(66,754	)		482,907
Net<br> change in cash and cash equivalents		(166,197	)		164,357
Cash<br> and cash equivalents, beginning of period		166,922			2,565
Cash<br> and cash equivalents, end of period	$	725		$	166,922
SUPPLEMENTAL<br> CASH FLOW INFORMATION
Cash<br> paid for interest	$	8,262		$	12,671

Seeaccompanying notes to the consolidated financial statements.

| F-5 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

JULY31, 2019 and JULY 31, 2018

NOTE1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

We are a healthcare technology company whose primary operations are through our IndeLiving subsidiary, which we acquired in March 2018. With the acquisition of IndeLiving, our core focus changed, and our operations through our Grasshopper Colorado subsidiary ceased in February 2019. We also changed our name to Healthcare Integrated Technologies, Inc., to better reflect our new operations. As a result, our operations, management and board of directors, and our business in general have undergone a substantial change and we have experienced a change in control since the closing of the IndeLiving acquisition.

The accounting policies used by us and our subsidiaries reflect industry practices and conform to U.S. generally accepted accounting principles (“GAAP”). Significant policies are discussed below.

Principlesof Consolidation

The accompanying consolidated financial statements include the accounts of Healthcare Integrated Technologies, Inc. and our subsidiaries (collectively, the “Company”). All intercompany balances and transactions are eliminated in the consolidation.

Reclassifications

Certain prior period amounts have been reclassified to conform to current period presentation.

Riskand Uncertainties

Factors that could affect our future operating results and cause actual results to vary materially from management’s expectation include, but are not limited to: our ability to maintain and secure adequate capital to fully develop our product(s) and operations; our ability to source strong opportunities with sufficient risk adjusted returns; acceptance of the terms and conditions of our licenses and/or the acceptance of our royalties and fees; the nature and extent of competition from other companies that may reduce market share and create pressure on pricing and investment return expectations; changes in the projects in which we plan to invest which result from factors beyond our control, including, but not limited to, a change in circumstances, capacity and economic impacts; changes in laws, regulations, accounting, taxation, and other requirements affecting our operations and business. Negative developments in these or other risk factors could have a significant adverse effect on our financial position, results of operations and cash flows.

Useof Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. We base our estimates on experience and various other assumptions that are believed to be reasonable under the circumstances. We evaluate our estimates and assumptions on a regular basis and actual results may differ from those estimates.

| F-6 |

| --- |

Cashand Cash Equivalents

We consider all highly liquid short-term investments with a maturity of three months or less at the time of purchase to be cash equivalents.

AccountsReceivable

Accounts receivable are stated at their historical carrying amount net of write-offs and allowance for uncollectible accounts. We routinely assess the recoverability of all customer and other receivables to determine their collectability and record a reserve when, based on the judgement of management, it is probably that a receivable will not be collected and the amount of the reserve may be reasonably estimated. When collection is no longer pursued, we charge uncollectable accounts receivable against the reserve. All our accounts receivable relates to our Grasshopper Staffing, Inc. subsidiary which eased operations in February 2019. At July 31, 2019, all accounts receivable were deemed uncollectable and the reserve for uncollectable accounts was increased accordingly.

Propertyand Equipment

Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for major additions and improvements are capitalized while minor replacements and maintenance and repairs, which do not improve or extend the life of such assets, are charged to operations as incurred. Disposals are removed at cost less accumulated depreciation, and any resulting gain or loss is reflected in the statement of operations. Depreciation is calculated using the straight-line method which depreciates the assets over the estimated useful lives of the depreciable assets ranging from five to seven years.

Long-lived assets such as property, equipment and identifiable intangibles are reviewed for impairment at least annually or whenever facts and circumstances indicate that the carrying value may not be recoverable. When required, impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. The Company did not recognize any impairment losses for any periods presented.

FairValue of Financial Instruments

Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:

Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.

Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.

Level 3 Inputs - Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity’s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.

Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and borrowings. The fair value of current financial assets and current financial liabilities approximates their carrying value because of the short-term maturity of these financial instruments.

| F-7 |

| --- |

RevenueRecognition

Prior to the discontinuance of its operations in February 2019, Grasshopper Colorado earned revenue by providing specialized temporary staffing solutions to the cannabis industry. We provided temporary labor at an agreed upon rate per hour. Billings were invoiced on a per-hour basis as the temporary staffing services were delivered to the customer. Revenue from most of our temporary staffing services was recognized at a point in time. We applied the practical expedient to recognize revenue for these services at various intervals based on the number of hours completed and the agreed upon rate per hour at that time.

Advertising

Advertising costs are expensed as incurred in accordance with ASC 720-35, “Advertising Costs.” We incurred advertising costs of $8,746 and $24,964 for the years ended July 31, 2019 and 2018, respectively, which are included in selling, general and administrative expenses on the consolidated financial statements.

NetLoss Per Common Share

We determine basic income (loss) per share and diluted income (loss) per share in accordance with the provisions of ASC 260, “Earnings Per Share.” Basic income (loss) per share excludes dilution and is computed by dividing earnings available to common stockholders by the weighted-average number of common shares outstanding for the period. The calculation of diluted income (loss) per share is similar to that of basic earnings per share, except the denominator is increased, if the earnings are positive, to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares had been exercised.

StockBased Compensation

The Company accounts for the grant of restricted stock awards in accordance with ASC 718, “Compensation-Stock Compensation.” ASC 718 requires companies to recognize in the statement of operations the grant-date fair value of equity-based compensation. The expense is recognized over the period during which the employee is required to provide service in exchange for the compensation. Any remaining unrecognized balance will be recognized ratably over the life of the vesting period and is a reduction of stockholders’ equity.

The Company accounts for non-employee share-based awards, if any, in accordance with the measurement and recognition criteria of ASC 505-50 “Equity-Based Payments to Non-Employees.”

BusinessCombinations

IncomeTaxes

Under ASC 740, “Income Taxes,” deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when it is more likely than not that some or all the deferred tax assets will not be realized. As of July 31, 2019 and July 31, 2018, there were no deferred taxes due to the uncertainty of the realization of net operating loss carry forwards prior to their expiration.

| F-8 |

| --- |

Statementof Comprehensive Income

No statement of comprehensive income is presented since net income (loss) and comprehensive income (loss) would be the same for all periods reported.

RecentAccounting Pronouncements

There are no recently issued accounting pronouncements that are expected to have a material impact on our financial condition, results of operations or cash flows.

NOTE2 - GOING CONCERN

The accompanying consolidated financial statements have been prepared in conformity with GAAP, which contemplates continuation of the Company as a going concern. We have a history of losses, an accumulated deficit, have negative working capital and have not generated cash from our operations to support a meaningful and ongoing business plan. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern.

In view of these matters, our ability to continue as a going concern is dependent upon the development, marketing and sales of a viable product to achieve a level of profitability. We intend on financing our future development activities and our working capital needs largely from the sale of private and public equity securities with additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should we be unable to continue as a going concern.

NOTE3 - ACQUISITION

On March 13, 2018 we entered into a Share Acquisition and Exchange Agreement with IndeLiving Holdings, Inc., a Florida corporation (“IndeLiving”), and its shareholders under which we acquired 100% of the outstanding capital stock of IndeLiving in exchange for 5,200,000 shares of our common stock.

As a result of the significant financial interest of our Chief Executive Officer and former member of IndeLiving, for financial statement reporting purposes, the merger between the Company and IndeLiving has been treated as a reverse acquisition with IndeLiving deemed the accounting acquirer, and the Company deemed the accounting acquiree under the acquisition method of accounting in accordance with section 805-10-55 of the FASB Accounting Standards Codification. The reverse acquisition is deemed a capital transaction and the net assets of IndeLiving (the accounting acquirer) are carried forward to the Company (the legal acquirer and the reporting entity) at their carrying value before the acquisition. The acquisition process utilizes the capital structure of the Company and the assets and liabilities of TW which are recorded at their historical cost. The equity of the Company is the historical equity of IndeLiving retroactively restated to reflect the number of shares issued by the Company in the transaction.

Purchase Price:
5,200,000<br> shares of common stock	$	22,751
Allocation<br> of Assets Acquired and Liabilities Assumed:
Cash	$	3,961
Furniture,<br> fixtures and equipment		24,600
Stock<br> subscription receivable		21,000
Accounts<br> payable		(18,148	)
Notes<br> payable		(8,662	)
Estimated<br> value of assets acquired<br> and liabilities assumed	$	22,751

NOTE4 - DISCONTINUED OPERATIONS

In February 2019, due to continuing operating losses, negative cash flow, limited prospects for future growth and a desire to focus on our healthcare technology products, management elected to discontinue the operations of its Grasshopper Colorado subsidiary. The loss from the operations from the subsidiary is presented separately on the consolidated income statement as discontinued operations.

Discontinued operations consisted of the following at July 31, 2019 and 2018:

	July<br> 31, 2019			July<br> 31, 2018
Net<br> revenue	$	27,909		$	115,614
Operating<br> expenses		(35,969	)		(188,636	)
Interest<br> expense		(7,534	)		(12,368	)
Loss<br> from discontinued operations	$	(15,594	)	$	(85,390	)

| F-9 |

| --- |

NOTE5 - ACCOUNTS RECEIVABLE

Accounts receivable, net consisted of the following at July 31, 2019 and 2018:

	July<br> 31, 2019			July<br> 31, 2018
Accounts<br> receivable	$	20,270		$	34,427
Less:<br> allowance for uncollectible accounts		(20,270	)		(19,900	)
Total<br> accounts receivable, net	$	-		$	14,527

Bad debt expense for the years ended July 31, 2019 and 2018 was $541 and $11,965 respectively.

NOTE6 - PROPERTY AND EQUIPMENT

Property and equipment, net consisted of the following at July 31, 2019 and 2018:

	July<br> 31, 2019			July<br> 31, 2018
Equipment	$	23,923		$	26,567
Furniture<br> and fixtures		-			3,006
Vehicles		14,766			14,766
Subtotal		38,689			44,339
Less:<br> accumulated depreciation		(20,297	)		(16,330	)
Total<br> property and equipment, net	$	18,392		$	28,009

Depreciation expense for the years ended July 31, 2019 and 2018 was $7,317 and $3,124 respectively.

NOTE7 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consisted of the following at July 31, 2019 and 2018:

	July 31, 2019		July 31, 2018
Accounts<br> payable	$	168,062	$	144,339
Accounts<br> payable, related party		203,582		192,427
Accrued<br> expenses, related party		138,216		181,833
Accrued<br> interest expense		52,266		14,063
Total<br> accounts payable and accrued expenses	$	562,126	$	532,662

NOTE8 - PAYROLL RELATED LIABILITIES

Payroll related liabilities consisted of the following at July 31, 2019 and 2018:

	July<br> 31, 2019		July<br> 31, 2018
Accrued<br> officer’s payroll	$	471,214	$	134,248
Accrued<br> payroll		-		10,556
Payroll<br> taxes payable		864		1,610
Total<br> payroll related liabilities	$	472,078	$	146,414

| F-10 |

| --- |

NOTE9 - DEBT

We had the following debt obligations reflected at their respective carrying values on our consolidated balance sheets as of July 31, 2019 and 2018:

	July<br> 31, 2019		July<br> 31, 2018
5%<br> Convertible promissory notes	$	750,000	$	750,000
Ford<br> Credit note		5,834		7,943
Total<br> debt obligations	$	755,834	$	757,943

5%Convertible Promissory Notes

On various dates during the month of March 2018 we issued a series of 5% Convertible Promissory Notes (collectively, the “5% Notes”) totaling $750,000 in net proceeds. We incurred no costs related to the issuance of the 5% Notes. The 5% Notes bear interest at the rate of five percent (5%) per annum, compounded annually and matured one-year from the date of issuance. At July 31, 2019 and 2018, accrued but unpaid interest on the 5% Notes was $52,266 and $14,063 respectively.

The 5% Notes are convertible into common shares of the Company at a fixed ratio of two shares of common stock per dollar amount of the face value of the note. The principal terms under which the 5% Notes may be converted into common stock of the Company are as follows:

●	At<br> the option of the holder, the outstanding principal amount of the note, and any accrued but unpaid interest due, may be converted<br> into the Company’s common stock at any time prior to the maturity date of the note.
●	The<br> outstanding principal amount of the note, and any accrued but unpaid interest due, will automatically be converted into the<br> Company’s common stock if at any time prior to the maturity date of the note, the Company concludes a sale of equity<br> securities in a private offering resulting in gross proceeds to the Company of at least $1,000,000.

The 5% Notes matured on various dates during March 2019 and are currently in default and are not convertible under the conversion terms. Management is currently negotiating an amendment to the 5% Notes to extend the maturity dates of the notes.

FordCredit Note

The Ford Credit note was assumed in the IndeLiving acquisition on March 13, 2018. The original retail installment contract was entered into on June 15, 2016 in the amount of $11,766. The note bears interest at 9.99% per annum and requires sixty (60) monthly installments of $251 per month. The installment note is collateralized by a 2013 Ford pickup truck.

NOTE10 - INCOME TAXES

On December 22, 2017, the Tax Cuts and Jobs Act (the “Act”) was signed into law and permanently reduced the corporate tax rate from 34% to 21% of taxable income. The Act was effective for tax years beginning on or after January 1, 2018. A reconciliation of the provision for income taxes as reported, and the amount computed by multiplying net loss by the federal statutory rate of 21% in fiscal 2019 and 34% in fiscal 2018 are as follows:

	July 31, 2019			July 31, 2018
Federal<br> income tax benefit computed at the statutory rate	$	(176,089	)	$	(697,480	)
Increase<br> (decrease) resulting from:
State<br> income taxes, net of federal benefit		(6,459	)		(4,419	)
Equity<br> based compensation		61,847			501,833
Revaluation<br> of deferred tax asset due to tax rate change		-			166,307
Valuation<br> allowance		119,019			10,832
Other		1,682			22,927
Income<br> tax benefit, as reported	$	-		$	-

| F-11 |

| --- |

Under the guidance of ASC 740, “Income Taxes,” We revalued our deferred tax asset on the date of enactment of the Tax Cuts and Jobs Act based on the reduction in the overall future tax benefit expected to be realized at the lower tax rate implemented by the new legislation. The components of the net deferred tax asset as of July 31, 2019 and 2018 are as follows:

	July 31, 2019			July 31, 2018
Deferred<br> tax assets:
Net<br> operating loss carryovers	$	404,651		$	451,939
Revaluation<br> of deferred tax asset due to tax rate change		-			(166,307	)
Valuation<br> allowance		(404,651	)		(285,632	)
Net<br> deferred tax asset, as reported	$	-		$	-

In assessing the realizable value of deferred tax assets, management considers whether it is more likely than not that some portion or all the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon generation of future taxable income during the periods in which these temporary differences become tax deductible. Based on management’s assessment of objective and subjective evidence, we have concluded at this time it is more likely than not that all of our deferred tax asset will not be realized and we have provided a valuation allowance for the entire amount of the deferred tax asset. At July 31, 2019 we have approximately $1.8 million in federal and state net operating loss carryovers that begin expiring in fiscal 2037.

We conduct business solely in the United States and file income tax returns in the United States federal jurisdiction as well as in the states of Tennessee and Colorado. The taxable years ended July 31, 2019, 2018 and 2017 remain open to examination by the taxing jurisdictions to which we are subject.

NOTE11 - RELATED PARTY TRANSACTIONS

In addition, we have accrued expenses related to the January 15, 2016 consulting and advisory agreement with Platinum Equity Advisors, LLC (the “Platinum Agreement”), a related party. The Platinum Agreement was terminated on March 12, 2018 (the “Termination Date”) when Scott M. Boruff, the Chief Manager of Platinum, was appointed Chief Executive Officer of the Company. As of July 31, 2019 and 2018, the accrued amount owed under the Platinum Agreement is $138,216 and $181,833, respectively.

NOTE12 - COMMON STOCK

At both July 31, 2019 and 2018, we had 32,487,500 shares of common stock outstanding. No shares were issued during the year ended July 31, 2019. We issued 6,200,000 shares during the year ended July 31, 2018, of which 1,000,000 were issued in exchange for warrants and 5,200,000 shares were issued for the acquisition of IndeLiving.

On February 21, 2018, we issued 1,000,000 shares of common stock to Acorn Management Partners, LLC (“Acorn”) in exchange for Acorn forfeiting warrants to purchase 6,000,000 shares of our common stock. The warrants had an exercise price of $0.01 and expired ten years from the date of issuance. The transaction terms were negotiated in good faith with an unrelated third party.

On March 13, 2018, we entered into a Share Acquisition and Exchange Agreement with IndeLiving and its shareholders, under which we acquired 100% of the outstanding capital stock of IndeLiving in exchange for 5,200,000 shares of our common stock. The net estimated value of the shares issued was $22,751, which equaled the estimated value of the net assets acquired.

| F-12 |

| --- |

NOTE13 - STOCK-BASED COMPENSATION

During the years ended July 31, 2019 and 2018, we recorded $294,510 and $120,701, respectively, of employee compensation expense related to stock options. No employee stock options were granted during the year ended July 31, 2019. The grant date fair value of employee stock options granted during the year ended July 31, 2018 was $1,178,040. We estimated the grant date fair value of employee stock options using the Black-Scholes pricing model with the following assumptions:


Expected<br> volatility	—	142	%
Expected<br> term (in years)	—	3.75
Risk-free<br> interest rate	—	2.52	%
Dividend<br> yield	—	None

ExpectedVolatility

Due to the fact we do not consider historical volatility is the best indicator of future volatility, we use implied volatility of our options to estimate future volatility.

ExpectedTerm

Where possible, we use the simplified method to estimate the expected term of employee stock options. Where we are unable to use the simplified method due to the terms of a stock option, we may use a modified simplified method to estimate the expected term. We do not have adequate historical exercise data to provide a reasonable basis for estimating the expected term for the current share options granted. The simplified method assumes that employees will exercise share options evenly between the period when the share options are vested and ending on the date when the options would expire.

Risk-FreeInterest Rate

The risk-free rate for the expected term of the option is based on the U.S. Treasury yield curve at the date of grant.

DividendYield

We have not estimated any dividend yield as we currently do not pay a dividend and do not anticipate paying a dividend over the expected term.

The following table summarizes our stock-based compensation activities for the years ended July 31, 2019 and 2018:

	July<br> 31, 2019				July<br> 31, 2018
	Number<br> of		Weighted		Number<br> of			Weighted
	Options<br> and		Average		Options<br> and			Average
	Warrants		Exercise<br> Price		Warrants			Exercise<br> Price
Balance<br> at beginning of year		2,500,000	$	3.00		6,000,000		$	0.01
Granted		-		-		2,500,000			3.00
Exercised		-		-		-			-
Canceled<br> (1)		-		-		(6,000,000	)		0.01
Balance<br> at end of year		2,500,000		3.00		2,500,000			3.00
Options<br> exercisable		625,000	$	3.00		-		$	-
(1)	On<br> February 21, 2018, we issued 1,000,000 shares of our common stock to Acorn Management Partners, LLC (“Acorn”)<br> in exchange for Acorn forfeiting warrants to purchase 6,000,000 shares of our common stock.
---	---

NOTE14 - RECENT ACCOUNTING PRONOUNCEMENTS

On January 1, 2018, we adopted Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers,” (“ASC Topic 606”) using the modified retrospective approach. Under this method, the Company follows the five-step model provided by ASC Topic 606 in order to recognize revenue in the following manner: 1) Identify the contract; 2) Identify the performance obligations of the contract; 3) Determine the transaction price of the contract; 4) Allocate the transaction price to the performance obligations; and 5) Recognize revenue. Under this method, an entity recognizes revenue for the transfer or promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. The Company’s revenue recognition policies remained substantially unchanged as a result of the adoption of ASU No. 2014-09, and there were no significant changes in business processes or systems.

NOTE15 - SUBSEQUENT EVENTS

On January 2, 2020, a sworn account lawsuit was filed against IndeLiving and our CEO Scott Boruff by our previous Certified Public Accounting Firm, RBSM LLP demanding payment of $28,007 for services rendered. We have filed our Answer and IndeLiving filed a breach of contract Counterclaim on February 24, 2020 demanding repayment of a $7,500 retainer paid to RBSM LLP by IndeLiving for services that we allege were not provided. Given the early state of the proceedings in this case, we currently cannot assess the probability of losses, but we can reasonably estimate that the range of losses in this case will be immaterial since the full amount of the lawsuit has previously been recorded in the consolidated financial statements.

On February 11, 2020, we completed a private placement of 1,000,000 shares of our common stock at a price of $.10 per share resulting in net proceeds to the Company of $100,000. We incurred no cost related to the private placement.

| F-13 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

INTERIMCONSOLIDATED BALANCE SHEETS

			July<br> 31, 2017

ASSETS
CURRENT<br> ASSETS
Cash<br> and cash equivalents	599,851		$	2,565
Accounts<br> receivable, net	19,980			42,950
Prepaid<br> expenses and other current assets	2,570			800
Total<br> current assets	622,401			46,315
Property<br> and equipment, net	26,624			3,259
Intangible<br> assets, net	-			840
Total<br> assets	649,025		$	50,414
LIABILITIES<br> AND STOCKHOLDERS’ DEFICIT
CURRENT<br> LIABILITIES:
Accounts<br> payable and accrued expenses	178,205		$	99,155
Accounts<br> payable and accrued expenses, related party	647,960			546,819
Payroll<br> related liabilities	61,632			78,670
Convertible<br> notes	750,000			-
Current<br> portion of long-term debt	2,471			-
Total<br> current liabilities	1,640,268			724,644
OTHER<br> LIABILITIES:
Long-term<br> debt	5,834			-
Total<br> liabilities	1,646,102			724,644
STOCKHOLDERS’<br> DEFICIT:
Common<br> stock par value 0.001; 200,000,000 shares authorized; 32,487,500 and 26,287,500 shares issued and outstanding as of April<br> 30, 2018 and July 31, 2017, respectively	32,488			26,288
Additional<br> paid-in capital	8,214,029			6,795,126
Accumulated<br> deficit	(9,243,594	)		(7,495,644	)
Total<br> stockholders’ deficit	(997,077	)		(674,230	)
Total<br> liabilities and stockholders’ deficit	649,025		$	50,414

All values are in US Dollars.

Seeaccompanying notes to the interim consolidated financial statements.

| F-14 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

INTERIMCONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For<br> the Three Months Ended						For<br> the Nine Months Ended
	April<br> 30,						April<br> 30,
	2018			2017			2018			2017
NET<br> REVENUES:
Contract<br> staffing services	$	90,622		$	72,859		$	376,367		$	249,342
Direct<br> cost of services		65,218			55,873			281,663			189,929
Gross<br> margin		25,404			16,986			94,704			59,413
OPERATING<br> EXPENSES:
Selling,<br> general and administrative		1,107,194			341,494			1,825,566			1,080,538
Total<br> operating expense		1,107,194			341,494			1,825,566			1,080,538
OPERATING<br> LOSS		(1,081,790	)		(324,508	)		(1,730,862	)		(1,021,125	)
OTHER<br> INCOME (EXPENSE):
Interest<br> expense		(9,817	)		(3,135	)		(17,088	)		(10,206	)
Other<br> income		-			-			-			2,950
Total<br> other income (expense)		(9,817	)		(3,135	)		(17,088	)		(7,256	)
NET<br> LOSS	$	(1,091,607	)	$	(327,643	)	$	(1,747,950	)	$	(1,028,381	)
NET<br> LOSS PER COMMON SHARE
Basic<br> and diluted	$	(0.04	)	$	(0.01	)	$	(0.06	)	$	(0.04	)
WEIGHTED<br> AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Basic<br> and diluted		28,070,915			26,287,500			27,227,346			26,287,500

Seeaccompanying notes to the interim consolidated financial statements.

| F-15 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

INTERIMCONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For<br> the Nine Months Ended
	April<br> 30,
	2018			2017
CASH<br> FLOWS FROM OPERATING ACTIVITIES
Net<br> loss	$	(1,747,950	)	$	(1,028,381	)
Adjustments<br> to reconcile loss to net cash used in operating activities:
Depreciation<br> and amortization		2,075			1,964
Provision<br> for doubtful accounts		11,965			-
Stock-based<br> compensation		1,402,351			697,000
Amortization<br> of deferred stock compensation, related parties		-			58,083
Revenue<br> factoring expense		-			8,744
Other<br> income		-			(2,950	)
Changes<br> in operating assets and liabilities (excluding effects of acquisitions):
Accounts<br> receivable, net		11,005			11,199
Prepaid<br> expenses and other current assets		(1,770	)		5,474
Accounts<br> payable and accrued expenses		27,976			7,884
Accounts<br> payable and accrued expenses, related party		128,740			180,000
Payroll<br> related liabilities		(17,038	)		15,176
NET<br> CASH USED BY OPERATING ACTIVITIES		(163,645	)		(45,807	)
CASH<br> FLOWS FROM INVESTING ACTIVITIES
Cash<br> acquired from acquisition of subsidiary		3,960			-
NET<br> CASH PROVIDED BY INVESTING ACTIVITIES		3,960			-
CASH<br> FLOWS FROM FINANCING ACTIVITIES
Proceeds<br> from issuance of convertible notes		750,000			-
Principal<br> payments of long-term debt		(356	)		-
Proceeds<br> from stock issuances		2,000			-
Proceeds<br> from third party loans		32,927			11,350
Proceeds<br> from related party loans		9,351			78,697
Payments<br> of amounts owed to related parties		(36,950	)		(11,705	)
Advances<br> under factoring arrangements		-			8,746
Repayments<br> under factoring arrangements		-			(41,281	)
NET<br> CASH PROVIDED BY FINANCING ACTIVITIES		756,972			45,807
Net<br> change in cash and cash equivalents		597,286			-
Cash<br> and cash equivalents, beginning of period		2,565			-
Cash<br> and cash equivalents, end of period	$	599,851		$	-
SUPPLEMENTAL<br> CASH FLOW INFORMATION
Cash<br> paid for interest	$	12,401		$	-

Seeaccompanying notes to the interim consolidated financial statements.

| F-16 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

INTERIMCONSOLIDATED BALANCE SHEETS

			July<br> 31, 2018

ASSETS
CURRENT<br> ASSETS
Cash<br> and cash equivalents	2,316		$	166,922
Accounts<br> receivable, net	20,540			14,527
Prepaid<br> expenses and other current assets	-			648
Total<br> current assets	22,856			182,097
Property<br> and equipment, net	25,938			28,009
Total<br> assets	48,794		$	210,106
LIABILITIES<br> AND STOCKHOLDERS’ DEFICIT
CURRENT<br> LIABILITIES:
Accounts<br> payable and accrued expenses	189,242		$	158,402
Accounts<br> payable and accrued expenses, related party	321,724			374,260
Payroll<br> related liabilities	228,669			146,414
Convertible<br> notes	750,000			750,000
Current<br> portion of long-term debt	2,787			2,718
Total<br> current liabilities	1,492,422			1,431,794
OTHER<br> LIABILITIES:
Long-term<br> debt	4,599			5,225
Total<br> liabilities	1,497,021			1,437,019
STOCKHOLDERS’<br> DEFICIT:
Common<br> stock par value 0.001; 200,000,000 shares authorized; 32,487,500 and 32,487,500 shares issued and outstanding as of October<br> 31, 2018 and July 31, 2018, respectively	32,488			32,488
Additional<br> paid-in capital	8,361,283			8,287,656
Accumulated<br> deficit	(9,841,998	)		(9,547,057	)
Total<br> stockholders’ deficit	(1,448,227	)		(1,226,913	)
Total<br> liabilities and stockholders’ deficit	48,794		$	210,106

All values are in US Dollars.

Seeaccompanying notes to the interim consolidated financial statements.

| F-17 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

INTERIMCONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For<br> the Three Months Ended
	October<br> 31,
	2018			2017
NET<br> REVENUES:
Contract<br> staffing services	$	67,973		$	196,013
Direct<br> cost of services		50,209			148,537
Gross<br> margin		17,764			47,476
OPERATING<br> EXPENSES:
Selling,<br> general and administrative		298,820			360,497
Total<br> operating expense		298,820			360,497
OPERATING<br> LOSS		(281,056	)		(313,021	)
OTHER<br> EXPENSE:
Interest<br> expense		(13,885	)		(442	)
Total<br> other expense		(13,885	)		(442	)
NET<br> LOSS	$	(294,941	)	$	(313,463	)
NET<br> LOSS PER COMMON SHARE
Basic<br> and diluted	$	(0.01	)	$	(0.01	)
WEIGHTED<br> AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Basic<br> and diluted		32,487,500			26,287,500

Seeaccompanying notes to the interim consolidated financial statements.

| F-18 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

INTERIMCONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For<br> the Three Months Ended
	October<br> 31,
	2018			2017
CASH<br> FLOWS FROM OPERATING ACTIVITIES
Net<br> loss	$	(294,941	)	$	(313,463	)
Adjustments<br> to reconcile loss to net cash used in operating activities:
Depreciation<br> and amortization		2,071			662
Provision<br> for doubtful accounts		-			(9,115	)
Stock-based<br> compensation		73,627			232,334
Other<br> income		-			(1,600	)
Changes<br> in operating assets and liabilities (excluding effects of acquisitions):
Accounts<br> receivable, net		(6,013	)		(10,451	)
Prepaid<br> expenses and other current assets		648			(5,552	)
Accounts<br> payable and accrued expenses		30,840			25,234
Accounts<br> payable and accrued expenses, related party		23,202			60,000
Payroll<br> related liabilities		82,255			16,668
NET<br> CASH USED BY OPERATING ACTIVITIES		(88,311	)		(5,283	)
CASH<br> FLOWS FROM FINANCING ACTIVITIES
Principal<br> payments of long-term debt		(557	)		-
Proceeds<br> from third party loans		-			12,500
Proceeds<br> from related party loans		62			850
Payments<br> of amounts owed to related parties		(75,800	)		-
NET<br> CASH (USED) PROVIDED BY FINANCING ACTIVITIES		(76,295	)		13,350
Net<br> change in cash and cash equivalents		(164,606	)		8,067
Cash<br> and cash equivalents, beginning of period		166,922			2,565
Cash<br> and cash equivalents, end of period	$	2,316		$	10,632
SUPPLEMENTAL<br> CASH FLOW INFORMATION
Cash<br> paid for interest	$	4,510		$	-

Seeaccompanying notes to the interim consolidated financial statements.

| F-19 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

INTERIMCONSOLIDATED BALANCE SHEETS

			July<br> 31, 2018

ASSETS
CURRENT<br> ASSETS
Cash<br> and cash equivalents	-		$	166,922
Accounts<br> receivable, net	8,284			14,527
Prepaid<br> expenses and other current assets	-			648
Total<br> current assets	8,284			182,097
Property<br> and equipment, net	23,868			28,009
Total<br> assets	32,152		$	210,106
LIABILITIES<br> AND STOCKHOLDERS’ DEFICIT
CURRENT<br> LIABILITIES:
Accounts<br> payable and accrued expenses	200,138		$	158,402
Accounts<br> payable and accrued expenses, related party	338,047			374,260
Payroll<br> related liabilities	305,568			146,414
Convertible<br> notes	750,000			750,000
Current<br> portion of long-term debt	2,859			2,718
Total<br> current liabilities	1,596,612			1,431,794
OTHER<br> LIABILITIES:
Long-term<br> debt	3,958			5,225
Total<br> liabilities	1,600,570			1,437,019
STOCKHOLDERS’<br> DEFICIT:
Common<br> stock par value 0.001; 200,000,000 shares authorized; 32,487,500 and 32,487,500 shares issued and outstanding as of January<br> 31, 2019 and July 31, 2018, respectively	32,488			32,488
Additional<br> paid-in capital	8,434,912			8,287,656
Accumulated<br> deficit	(10,035,818	)		(9,547,057	)
Total<br> stockholders’ deficit	(1,568,418	)		(1,226,913	)
Total<br> liabilities and stockholders’ deficit	32,152		$	210,106

All values are in US Dollars.

Seeaccompanying notes to the interim consolidated financial statements.

| F-20 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

INTERIMCONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For<br> the Three Months Ended						For<br> the Six Months Ended
	January<br> 31,						January<br> 31,
	2019			2018			2019			2018
NET<br> REVENUES:
Contract<br> staffing services	$	31,174		$	89,732		$	99,147		$	285,745
Direct<br> cost of services		20,967			67,908			71,176			216,445
Gross<br> margin		10,207			21,824			27,971			69,300
OPERATING<br> EXPENSES:
Selling,<br> general and administrative		193,273			357,875			492,092			718,372
Total<br> operating expense		193,273			357,875			492,092			718,372
OPERATING<br> LOSS		(183,066	)		(336,051	)		(464,121	)		(649,072	)
OTHER<br> EXPENSE:
Interest<br> expense		(10,754	)		(6,829	)		(24,639	)		(7,271	)
Total<br> other expense		(10,754	)		(6,829	)		(24,639	)		(7,271	)
NET<br> LOSS	$	(193,820	)	$	(342,880	)	$	(488,760	)	$	(656,343	)
NET<br> LOSS PER COMMON SHARE
Basic<br> and diluted	$	(0.01	)	$	(0.01	)	$	(0.02	)	$	(0.02	)
WEIGHTED<br> AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Basic<br> and diluted		32,487,500			26,287,500			32,487,500			26,287,500

Seeaccompanying notes to the interim consolidated financial statements.

| F-21 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

INTERIMCONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For<br> the Six Months Ended
	January<br> 31,
	2019			2018
CASH<br> FLOWS FROM OPERATING ACTIVITIES
Net<br> loss	$	(488,760	)	$	(656,343	)
Adjustments<br> to reconcile loss to net cash used in operating activities:
Depreciation<br> and amortization		4,141			1,323
Provision<br> for doubtful accounts		-			(9,115	)
Stock-based<br> compensation		147,255			464,667
Other<br> income		-			(1,600	)
Changes<br> in operating assets and liabilities (excluding effects of acquisitions):
Accounts<br> receivable, net		6,243			24,911
Prepaid<br> expenses and other current assets		648			(3,630	)
Accounts<br> payable and accrued expenses		41,736			35,852
Accounts<br> payable and accrued expenses, related party		32,183			120,000
Payroll<br> related liabilities		159,154			(9,162	)
NET<br> CASH USED BY OPERATING ACTIVITIES		(97,400	)		(33,097	)
CASH<br> FLOWS FROM FINANCING ACTIVITIES
Principal<br> payments of long-term debt		(1,126	)		-
Proceeds<br> from third party loans		-			27,150
Proceeds<br> from related party loans		7,404			8,350
Payments<br> of amounts owed to related parties		(75,800	)		-
NET<br> CASH (USED) PROVIDED BY FINANCING ACTIVITIES		(69,522	)		35,500
Net<br> change in cash and cash equivalents		(166,922	)		2,403
Cash<br> and cash equivalents, beginning of period		166,922			2,565
Cash<br> and cash equivalents, end of period	$	-		$	4,968
SUPPLEMENTAL<br> CASH FLOW INFORMATION
Cash<br> paid for interest	$	5,889		$	-

Seeaccompanying notes to the interim consolidated financial statements.

| F-22 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

INTERIMCONSOLIDATED BALANCE SHEETS

			July<br> 31, 2018

ASSETS
CURRENT<br> ASSETS
Cash<br> and cash equivalents	-		$	166,922
Accounts<br> receivable, net	370			14,527
Prepaid<br> expenses and other current assets	-			648
Total<br> current assets	370			182,097
Property<br> and equipment, net	21,805			28,009
Total<br> assets	22,175		$	210,106
LIABILITIES<br> AND STOCKHOLDERS’ DEFICIT
CURRENT<br> LIABILITIES:
Accounts<br> payable and accrued expenses	211,386		$	158,402
Accounts<br> payable and accrued expenses, related party	340,198			374,260
Payroll<br> related liabilities	388,878			146,414
Convertible<br> notes	750,000			750,000
Current<br> portion of long-term debt	3,129			2,718
Total<br> current liabilities	1,693,591			1,431,794
OTHER<br> LIABILITIES:
Long-term<br> debt	3,300			5,225
Total<br> liabilities	1,696,891			1,437,019
STOCKHOLDERS’<br> DEFICIT:
Common<br> stock par value 0.001; 200,000,000 shares authorized; 32,487,500 and 32,487,500 shares issued and outstanding as of April<br> 30, 2019 and July 31, 2018, respectively	32,488			32,488
Additional<br> paid-in capital	8,508,538			8,287,656
Accumulated<br> deficit	(10,215,742	)		(9,547,057	)
Total<br> stockholders’ deficit	(1,674,716	)		(1,226,913	)
Total<br> liabilities and stockholders’ deficit	22,175		$	210,106

All values are in US Dollars.

Seeaccompanying notes to the interim consolidated financial statements.

| F-23 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

INTERIMCONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For<br> the Three Months Ended						For<br> the Nine Months Ended
	April<br> 30,						April<br> 30,
	2019			2018			2019			2018
NET<br> REVENUES:
Contract<br> staffing services	$	-		$	-		$	-		$	-
Direct<br> cost of services		-			-			-			-
Gross<br> margin		-			-			-			-
OPERATING<br> EXPENSES:
Selling,<br> general and administrative		166,272			963,168			623,944			1,654,868
Total<br> operating expense		166,272			963,168			623,944			1,654,868
OPERATING<br> LOSS		(166,272	)		(963,168	)		(623,944	)		(1,654,868	)
OTHER<br> EXPENSE:
Interest<br> expense		(9,742	)		(3,957	)		(28,929	)		(4,832	)
Total<br> other expense		(9,742	)		(3,957	)		(28,929	)		(4,832	)
LOSS<br> FROM CONTINUING OPERATIONS		(176,014	)		(967,125	)		(652,873	)		(1,659,700	)
LOSS<br> FROM DISCONTINUED OPERATIONS		(3,911	)		(124,482	)		(15,813	)		(88,250	)
NET<br> LOSS	$	(179,925	)	$	(1,091,607	)	$	(668,686	)	$	(1,747,950	)
NET<br> LOSS PER COMMON SHARE
Basic<br> and diluted	$	(0.01	)	$	(0.04	)	$	(0.02	)	$	(0.06	)
WEIGHTED<br> AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Basic<br> and diluted		32,487,500			28,070,915			32,487,500			27,227,346

Seeaccompanying notes to the interim consolidated financial statements.

| F-24 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

INTERIMCONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For<br> the Nine Months Ended
	April<br> 30,
	2019			2018
CASH<br> FLOWS FROM OPERATING ACTIVITIES
Net<br> loss	$	(668,686	)	$	(1,747,950	)
Adjustments<br> to reconcile loss to net cash used in operating activities:
Depreciation<br> and amortization		6,204			2,075
Provision<br> for doubtful accounts		-			11,965
Stock-based<br> compensation		220,882			1,402,351
Changes<br> in operating assets and liabilities (excluding effects of acquisitions):
Accounts<br> receivable, net		14,157			11,005
Prepaid<br> expenses and other current assets		648			(1,770	)
Accounts<br> payable and accrued expenses		52,984			27,977
Accounts<br> payable and accrued expenses, related party		32,184			147,742
Payroll<br> related liabilities		242,464			(17,038	)
NET<br> CASH USED BY OPERATING ACTIVITIES		(99,163	)		(163,643	)
CASH<br> FLOWS FROM INVESTING ACTIVITIES
Cash<br> acquired from acquisition of subsidiary		-			3,960
NET<br> CASH PROVIDED BY INVESTING ACTIVITIES		-			3,960
CASH<br> FLOWS FROM FINANCING ACTIVITIES
Proceeds<br> from issuance of convertible notes		-			750,000
Proceeds<br> from stock issuances		-			2,000
Principal<br> payments of long-term debt		(1,514	)		(356	)
Proceeds<br> from third party loans		-			32,925
Proceeds<br> from related party loans		9,555			9,350
Payments<br> of amounts owed to related parties		(75,800	)		(36,950	)
NET<br> CASH (USED) PROVIDED BY FINANCING ACTIVITIES		(67,759	)		756,969
Net<br> change in cash and cash equivalents		(166,922	)		597,286
Cash<br> and cash equivalents, beginning of period		166,922			2,565
Cash<br> and cash equivalents, end of period	$	-		$	599,851
SUPPLEMENTAL<br> CASH FLOW INFORMATION
Cash<br> paid for interest	$	7,527		$	12,401

Seeaccompanying notes to the interim consolidated financial statements.

| F-25 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

INTERIMCONSOLIDATED BALANCE SHEETS

			July<br> 31, 2019

ASSETS
CURRENT<br> ASSETS
Cash<br> and cash equivalents	386		$	725
Total<br> current assets	386			725
Property<br> and equipment, net	16,562			18,392
Total<br> assets	16,948		$	19,117
LIABILITIES<br> AND STOCKHOLDERS’ DEFICIT
CURRENT<br> LIABILITIES:
Accounts<br> payable and accrued expenses	230,196		$	220,328
Accounts<br> payable and accrued expenses, related party	356,154			341,798
Payroll<br> related liabilities	557,400			472,078
Convertible<br> notes	750,000			750,000
Current<br> portion of long-term debt	3,901			3,209
Total<br> current liabilities	1,897,651			1,787,413
OTHER<br> LIABILITIES:
Long-term<br> debt	1,933			2,625
Total<br> liabilities	1,899,584			1,790,038
STOCKHOLDERS’<br> DEFICIT:
Common<br> stock par value 0.001; 200,000,000 shares authorized; 32,487,500 and 32,487,500 shares issued and outstanding as of October<br> 31, 2019 and July 31, 2019, respectively	32,488			32,488
Additional<br> paid-in capital	8,657,360			8,582,166
Accumulated<br> deficit	(10,572,484	)		(10,385,575	)
Total<br> stockholders’ deficit	(1,882,636	)		(1,770,921	)
Total<br> liabilities and stockholders’ deficit	16,948		$	19,117

All values are in US Dollars.

Seeaccompanying notes to the interim consolidated financial statements.

| F-26 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

INTERIMCONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For<br> the Three Months Ended
	October<br> 31,
	2019			2018
NET<br> REVENUES:
Contract<br> staffing services	$	-		$	-
Direct<br> cost of services		-			-
Gross<br> margin		-			-
OPERATING<br> EXPENSES:
Selling,<br> general and administrative		175,970			277,692
Total<br> operating expense		175,970			277,692
OPERATING<br> LOSS		(175,970	)		(277,692	)
OTHER<br> EXPENSE:
Interest<br> expense		(9,844	)		(13,885	)
Total<br> other expense		(9,844	)		(13,885	)
LOSS<br> FROM CONTINUING OPERATIONS		(185,814	)		(291,577	)
LOSS<br> FROM DISCONTINUED OPERATIONS		(1,095	)		(3,364	)
NET<br> LOSS	$	(186,909	)	$	(294,941	)
NET<br> LOSS PER COMMON SHARE
Basic<br> and diluted	$	(0.01	)	$	(0.01	)
WEIGHTED<br> AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Basic<br> and diluted		32,487,500			32,487,500

Seeaccompanying notes to the interim consolidated financial statements.

| F-27 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

INTERIMCONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For<br> the Three Months Ended
	October<br> 31,
	2019			2018
CASH<br> FLOWS FROM OPERATING ACTIVITIES
Net<br> loss	$	(186,909	)	$	(294,941	)
Adjustments<br> to reconcile loss to net cash used in operating activities:
Depreciation<br> and amortization		1,829			2,071
Stock-based<br> compensation		75,194			73,627
Changes<br> in operating assets and liabilities (excluding effects of acquisitions):
Accounts<br> receivable, net		-			(6,013	)
Prepaid<br> expenses and other current assets		-			648
Accounts<br> payable and accrued expenses		9,867			30,839
Accounts<br> payable and accrued expenses, related party		5,050			23,202
Payroll<br> related liabilities		85,322			82,255
NET<br> CASH USED BY OPERATING ACTIVITIES		(9,646	)		(88,312	)
CASH<br> FLOWS FROM FINANCING ACTIVITIES
Principal<br> payments of long-term debt		-			(557	)
Proceeds<br> from related party loans		9,307			63
Payments<br> of amounts owed to related parties		-			(75,800	)
NET<br> CASH (USED) PROVIDED BY FINANCING ACTIVITIES		9,307			(76,294	)
Net<br> change in cash and cash equivalents		(339	)		(164,606	)
Cash<br> and cash equivalents, beginning of period		725			166,922
Cash<br> and cash equivalents, end of period	$	386		$	2,316
SUPPLEMENTAL<br> CASH FLOW INFORMATION
Cash<br> paid for interest	$	802		$	4,510

Seeaccompanying notes to the interim consolidated financial statements.

| F-28 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

INTERIMCONSOLIDATED BALANCE SHEETS

			July<br> 31, 2019

ASSETS
CURRENT<br> ASSETS
Cash<br> and cash equivalents	108		$	725
Total<br> current assets	108			725
Property<br> and equipment, net	14,733			18,392
Total<br> assets	14,841		$	19,117
LIABILITIES<br> AND STOCKHOLDERS’ DEFICIT
CURRENT<br> LIABILITIES:
Accounts<br> payable and accrued expenses	260,786		$	220,328
Accounts<br> payable and accrued expenses, related party	375,559			341,798
Payroll<br> related liabilities	657,284			472,078
Convertible<br> notes	750,000			750,000
Current<br> portion of long-term debt	3,586			3,209
Total<br> current liabilities	2,047,215			1,787,413
OTHER<br> LIABILITIES:
Long-term<br> debt	1,224			2,625
Total<br> liabilities	2,048,439			1,790,038
STOCKHOLDERS’<br> DEFICIT:
Common<br> stock par value 0.001; 200,000,000 shares authorized; 32,487,500 and 32,487,500 shares issued and outstanding as of January<br> 31, 2020 and July 31, 2019, respectively	32,488			32,488
Additional<br> paid-in capital	8,736,994			8,582,166
Accumulated<br> deficit	(10,803,080	)		(10,385,575	)
Total<br> stockholders’ deficit	(2,033,598	)		(1,770,921	)
Total<br> liabilities and stockholders’ deficit	14,841		$	19,117

All values are in US Dollars.

Seeaccompanying notes to the interim consolidated financial statements.

| F-29 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

INTERIMCONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For the Three Months Ended						For the Six Months Ended
	January 31,						January 31,
	2020			2019			2020			2019
NET REVENUES:
Contract<br> staffing services	$	-		$	-		$	-		$	-
Direct<br> cost of services		-			-			-			-
Gross<br> margin		-			-			-			-
OPERATING EXPENSES:
Selling,<br> general and administrative		220,119			179,980			396,089			457,671
Total<br> operating expense		220,119			179,980			396,089			457,671
OPERATING LOSS		(220,119	)		(179,980	)		(396,089	)		(457,671	)
OTHER EXPENSE:
Interest<br> expense		(10,074	)		(5,302	)		(19,918	)		(19,187	)
Total<br> other expense		(10,074	)		(5,302	)		(19,918	)		(19,187	)
LOSS FROM CONTINUING OPERATIONS		(230,193	)		(185,282	)		(416,007	)		(476,858	)
LOSS FROM DISCONTINUED OPERATIONS		(403	)		(8,538	)		(1,498	)		(11,902	)
NET LOSS	$	(230,596	)	$	(193,820	)	$	(417.505	)	$	(488,760	)
NET LOSS PER COMMON SHARE
Basic<br> and diluted	$	(0.01	)	$	(0.01	)	$	(0.01	)	$	(0.02	)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Basic<br> and diluted		32,487,500			32,487,500			32,487,500			32,487,500

Seeaccompanying notes to the interim consolidated financial statements.

| F-30 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

INTERIMCONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For<br> the Six Months Ended
	January<br> 31,
	2020			2019
CASH<br> FLOWS FROM OPERATING ACTIVITIES
Net<br> loss	$	(417,505	)	$	(488,760	)
Adjustments<br> to reconcile loss to net cash used in operating activities:
Depreciation<br> and amortization		3,659			4,141
Provision<br> for doubtful accounts		-			-
Stock-based<br> compensation		154,828			147,255
Changes<br> in operating assets and liabilities (excluding effects of acquisitions):
Accounts<br> receivable, net		-			6,243
Prepaid<br> expenses and other current assets		-			648
Accounts<br> payable and accrued expenses		40,458			41,146
Accounts<br> payable and accrued expenses, related party		5,050			32,183
Payroll<br> related liabilities		185,206			159,154
NET<br> CASH USED BY OPERATING ACTIVITIES		(28,305	)		(97,990	)
CASH<br> FLOWS FROM FINANCING ACTIVITIES
Principal<br> payments of long-term debt		(1,024	)		(1,126	)
Proceeds<br> from related party loans		28,712			7,405
Payments<br> of amounts owed to related parties		-			(75,800	)
NET<br> CASH (USED) PROVIDED BY FINANCING ACTIVITIES		27,688			(69,521	)
Net<br> change in cash and cash equivalents		(617	)		(167,511	)
Cash<br> and cash equivalents, beginning of period		725			166,922
Cash<br> and cash equivalents, end of period	$	108		$	(589	)
SUPPLEMENTAL<br> CASH FLOW INFORMATION
Cash<br> paid for interest	$	1,032		$	5,889

Seeaccompanying notes to the interim consolidated financial statements.

| F-31 |

| --- |

HEALTHCAREINTEGRATED TECHNOLOGIES, INC.

NOTESTO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE1 - BASIS OF PRESENTATION

The interim financial statements presented herein have been prepared by Healthcare Integrated Technologies, Inc. (the “Company”) without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Where the interim financial statements include comparative balances from the periods ended July 31, 2019, 2018 and 2017, these balances were derived from audited financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”) have been omitted pursuant to such rules and regulations, although we believe that the disclosures are adequate to make the information presented not misleading.

These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. Interim results are not necessarily indicative of results for a full year. We recommend that these interim financial statements be read in conjunction with the financial statements and accompanying notes included in the Company’s annual report for the fiscal year ended July 31, 2019. We follow the same accounting policies in preparation of interim reports as we do in our annual reports.

NOTE2 - GOING CONCERN

We have a history of losses, an accumulated deficit, have negative working capital and have not generated cash flow from our operations to support a meaningful and ongoing business plan. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern.

In view of these matters, our ability to continue as a going concern is dependent upon the development, marketing and sales of a viable product to achieve a level of profitability. We intend on financing our future development activities and our working capital needs largely from the sale of private and public equity securities with additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The unaudited, interim financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should we be unable to continue as a going concern.

NOTE3 - CONTINGENCY

On January 2, 2020, a sworn account lawsuit was filed against our IndeLiving Holdings, Inc. (“IndeLiving”) subsidiary and our CEO Scott M. Boruff by our previous Certified Public Accounting Firm, RBSM LLP demanding payment of $28,007 for services rendered. We have filed our Answer and IndeLiving filed a breach of contract Counterclaim on February 24, 2020 demanding repayment of a $7,500 retainer paid to RBSM LLP by IndeLiving for services that we allege were not provided. Given the early state of the proceedings in this case, we currently cannot assess the probability of losses, but we can reasonably estimate that the range of losses in this case will be immaterial since the full amount of the lawsuit has previously been recorded in the consolidated financial statements.

NOTE4 - SUBSEQUENT EVENTS

| F-32 |

| --- |

Exhibit31.1

CERTIFICATIONOF PRINCIPAL EXECUTIVE OFFICER

PURSUANTTO 18 U.S.C. SECTION 1350,

ASADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEYACT OF 2002

I, Scott M. Boruff, certify that:

1.	I have reviewed this annual report on Form 10-K of Healthcare Integrated Technologies, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3.	Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
	a)	designed<br> such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,<br> to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to<br> us by others within those entities, particularly during the period in which this quarterly report is being prepared;
	b)	designed<br> such internal control over financial reporting, or caused such internal control over financial reporting to be designed under<br> our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial<br> statements for external purposes in accordance with generally accepted accounting principles;
	c)	evaluated<br> the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions<br> about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based<br> on such evaluation;
	d)	disclosed<br> in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s<br> most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an quarterly report) that has materially<br> affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;
5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):
	a)	all<br> significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting<br> which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial<br> information; and
	b)	any<br> fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s<br> internal controls over financial reporting.
Date:<br> March 20, 2020	By:	/s/ Scott M. Boruff
---	---	---
		Scott<br> M. Boruff<br><br> <br>Chief<br> Executive Officer,<br><br> <br>(Principal<br> Executive Officer)

CERTIFICATIONOF PRINCIPAL FINANCIAL OFFICER

PURSUANTTO 18 U.S.C. SECTION 1350,

ASADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEYACT OF 2002

I, Charles B. Lobetti, III, certify that:

1.	I<br> have reviewed this annual report on Form 10-K of Healthcare Integrated Technologies, Inc.;
2.	Based<br> on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary<br> to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect<br> to the period covered by this quarterly report;
3.	Based<br> on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present<br> in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the<br> periods presented in this quarterly report;
4.	The<br> registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and<br> procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined<br> in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)	designed<br> such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,<br> to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to<br> us by others within those entities, particularly during the period in which this quarterly report is being prepared;
---	---
b)	designed<br> such internal control over financial reporting, or caused such internal control over financial reporting to be designed under<br> our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial<br> statements for external purposes in accordance with generally accepted accounting principles;
c)	evaluated<br> the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions<br> about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based<br> on such evaluation;
d)	disclosed<br> in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s<br> most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an quarterly report) that has materially<br> affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;
5.	The<br> registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control<br> over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors<br> (or persons performing the equivalent function):
---	---	---
	a)	all<br> significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting<br> which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial<br> information; and
	b)	any<br> fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s<br> internal controls over financial reporting.
Date:<br> March 20, 2020	By:	/s/ Charles B. Lobetti, III
---	---	---
		Charles<br> B. Lobetti, III<br><br> <br>Chief<br> Financial Officer,<br><br> <br>(Principal<br> Financial Officer)

Exhibit32.1

CERTIFICATIONOF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Healthcare Integrated Technologies, Inc., (the “Company”) on Form 10-K for the years ended July 31, 2019 and July 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Scott M. Boruff, Chief Executive Officer of the Company, certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully<br>complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 20, 2020	By:	/s/ Scott M. Boruff
---	---	---
		Scott M. Boruff<br><br> <br>Chief Executive Officer<br><br> <br>(Principal Executive Officer)

CERTIFICATIONOF PRINCIPAL FINANCIAL OFFICER

PURSUANTTO 18 U.S.C. SECTION 1350,

ASADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEYACT OF 2002

In connection with the Annual Report of Healthcare Integrated Technologies, Inc., (the “Company”) on Form 10-K for the years ended July 31, 2019 and July 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Charles B. Lobetti, III, Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:

(1)	The<br>Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The<br> information contained in the Report fairly presents, in all material respects, the financial condition and results of operations<br> of the Company.
Date:<br> March 20, 2020	By:	/s/ Charles B. Lobetti, III
---	---	---
		Charles<br> B. Lobetti, III<br><br> <br>Chief<br> Financial Officer<br><br> <br>(Principal<br> Financial Officer)